45700

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Medicare \& Medicaid Services

## 42 CFR Parts 410, 416, and 419

[CMS-1414-CN2]
RIN 0938-AP41

## Medicare Program: Changes to the Hospital Outpatient Prospective Payment System and CY 2010 Payment Rates; Changes to the Ambulatory Surgical Center Payment System and CY 2010 Payment Rates; Corrections

AGENCY: Centers for Medicare \& Medicaid Services (CMS), HHS.
ACTION: Correction of final rule with comment period.

SUMMARY: This document corrects technical errors that appeared in the final rule with comment period found in the Federal Register (FR) on November 20, 2009, entitled "Medicare Program: Changes to the Hospital Outpatient Prospective Payment System and CY 2010 Payment Rates; Changes to the Ambulatory Surgical Center Payment System and CY 2010 Payment Rates" and in the correction document found in the Federal Register on December 31, 2009, entitled "Medicare Program: Changes to the Hospital Outpatient Prospective Payment System and CY 2010 Payment Rates; Changes to the Ambulatory Surgical Center Payment System and CY 2010 Payment Rates."
DATES: Effective Date: This document is effective on August 3, 2010.

Applicability Date: The corrections in this document are applicable on and after January 1, 2010.

## FOR FURTHER INFORMATION CONTACT:

 Alberta Dwivedi, (410) 786-0378.SUPPLEMENTARY INFORMATION:

## I. Background

In FR Doc. E0-26499 of November 20, 2009 (74 FR 60316) (hereinafter referred to as the CY 2010 OPPS/ASC final rule), there were several technical and typographic errors. Some of these errors were corrected in the correction document of December 31, 2009 (74 FR 69502) (hereinafter referred to as the December 31, 2009 CY 2010 OPPS/ASC correction document). We identified additional errors to the practice expense (PE) relative value units (RVUs) and the conversion factor (CF) for the Medicare Physician Fee Schedule (MPFS) in the November 25, 2009 Medicare Program; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2010 final rule with
comment period (74 FR 61738)
(hereinafter referred to as the CY 2010 MPFS final rule), which were corrected in the May 11, 2010 CY 2010 MPFS correction document ( 75 FR 26350). The revised ASC payment system uses the PE RVUs and the CF for the MPFS as part of the office-based and ancillary radiology payment methodology. This notice updates the CY 2010 OPPS/ASC final rule to include these additional corrections.

The provisions in this correction document are effective as if they had been included in the CY 2010 OPPS/ ASC final rule appearing in the November 20, 2009 Federal Register (74 FR 60316). Accordingly, the corrections are effective January 1, 2010.

## II. Summary of Errors

A. Errors in the December 31, 2009 Correction

In the December 31, 2009 CY 2010 OPPS/ASC correction document, we republished Addendum AA on pages 69505 through 69629 and Addendum BB on pages 69630 through 69675 to take into account updated CY 2010 MPFS information. As required under §416.171(d), the revised ASC payment system limits payment for office-based procedures and covered ancillary radiology services to the lesser of the ASC rate or the amount calculated by multiplying the nonfacility PE RVUs for the service by the CF under the MPFS However, the MPFS CF and PE RVUs listed for some CPT codes in Addendum B to the CY 2010 MPFS final rule ( 74 FR 62017) were incorrect due to certain technical errors and, consequently, were corrected in a December 10, 2009 correction document to the CY 2010 MPFS final rule ( 74 FR 65450). Since the ASC payment amounts for officebased procedures and covered ancillary radiology services are determined using the amounts in the MPFS final rule, we corrected the CY 2010 payment amounts for ASC procedures and services using the corrected MPFS amounts in the December 31, 2009 CY 2010 OPPS/ASC correction document.

Additional technical and
typographical errors were discovered in the CY 2010 MPFS final rule, as well as the December 10, 2009 CY 2010 MPFS correction document. These changes were corrected in the May 11, 2010 CY 2010 MPFS correction document (75 FR 26350). That correction document:

- Made corrections to the PE and malpractice (MP) RVUs to align their values to the final CY 2010 MPFS policies for PE and MP RVUs; and
- Made corrections to the CF resulting from corrections to the PE and

MP RVUs to align their values with the final CY 2010 MPFS policies for PE and MP RVUs, taking into consideration comments received from the public and further review following display of the CY 2010 MPFS final rule.
We refer readers to the May 11, 2010 CY 2010 MPFS correction document (75 FR 26350) for more information on the changes made to the MPFS.
In summary, addenda AA and BB in the December 31, 2009 CY 2010 OPPS/ ASC correction document contained errors in the rates for surgical procedures designated as office-based and for covered ancillary radiology procedures which are corrected in this notice.

## B. Correction of Errors in the December 31, 2010 Correction

The changes to the MPFS impacted multiple codes within Addenda AA and BB. Therefore, we are republishing Addenda AA and BB, which were republished on pages 69505 through 69629 and 69630 through 69675 of the December 31, 2009 CY 2010 OPPS/ASC correction document to take into account the updated CY 2010 MPFS information. The ASC payment amounts for office-based procedures and covered ancillary radiology services are determined using the MPFS final calendar year CF and PE RVUs. We must correct the CY 2010 payment amounts for covered office-based procedures and covered ancillary radiology services using the final CY 2010 corrected MPFS values. The revised rates continue to reflect the negative update to the MPFS for CY 2010 based on current law at the time of publication of the CY 2010 MPFS final rule and the corrections to the RVUs and CFs. The corrected payment amounts are reflected in Addenda AA and $B B$ to this correction document and also are posted on the CMS Web site at: http://www.cms.gov/ASCPayment.

We note that the Department of Defense Appropriations Act, 2010 (Pub. L. 111-118), the Temporary Extension Act of 2010 (Pub. L. 111-144), and the Continuing Extension Act of 2010 (Pub. L. 111-157) extended a zero percent update for the MPFS from January 1, 2010 through May 31, 2010. We are publishing a notice around the same time as this correction document announcing certain provision of the Patient Protection and Affordable Care Act (Affordable Care Act), as amended by the Health Care and Education Reconciliation Act of 2010 (HCERA), for CY 2010. Because the changes required by the Affordable Care Act and HCERA are effective January 1, 2010, and because the public laws listed above
authorize a zero percent update for the MPFS for CY 2010 through May 31, 2010, the notice incorporates a zero percent update for MPFS payment. If Congress chooses not to extend the zero percent MPFS update beyond May 31, 2010 or chooses to revise the MPFS update to be something other than zero, we will recalculate the payment rates presented in that notice based on the CY 2010 MPFS payment rates calculated using the revised update factor.
The payment rates presented in this correction document technical corrections made to the CY 2010 OPPS/ ASC final rule and will not be used for payment. The payment rates presented in the notice being published around the same time as this correction document are the final ASC payment rates from January 1, 2010, through May 31, 2010. We recalculated the ASC payment rates, including budget neutrality calculations, in that notice to reflect changes created by the Affordable Care Act and HCERA, and the technical corrections addressed in this correction document.

## IV. Waiver of Proposed Rulemaking and Delay in Effective Date

We ordinarily publish a notice of proposed rulemaking in the Federal

Register to provide a period for public comment before the provisions of a notice such as this take effect, in accordance with the Administrative Procedure Act (APA) (5 U.S.C. 553(b)). We also ordinarily provide a 30 -day delay in the effective date of the provisions of a notice in accordance with the APA (5 U.S.C. 553(d)). However, we can waive both the notice and comment procedures and the $30-$ day delay in the effective date if the Secretary finds, for good cause, that it is impracticable, unnecessary or contrary to the public interest to follow the notice and comment procedures or to comply with the 30-day delay in the effective date, and incorporates a statement of the finding and the reasons therefor in the notice. This correction document merely provides technical corrections to the CY 2010 OPPS/ASC final rule, as corrected by the December 31, 2009 CY 2010 OPPS/ASC correction document, that was effective on January 1, 2010. The provisions of the CY 2010 OPPS/ASC final rule were promulgated through notice and comment rulemaking, and the corrections contained in this document do not make substantive changes to the policies or payment methodologies that were
finalized in the CY 2010 OPPS/ASC final rule. In addition, we believe it is in the public interest to have the correct information and to have it as soon as possible and not delay its dissemination. For the reasons stated above, we find that both notice and comment procedures and the 30-day delay in effective date for this correction document are unnecessary and contrary to the public interest. Therefore, we find there is good cause to waive notice and comment procedures and the 30-day delay in effective date for this correction document.
(Catalog of Federal Domestic Assistance Program No. 93.774, MedicareSupplementary Medical Insurance Program)

Dated: June 24, 2010.

## Dawn L. Smalls,

Executive Secretary to the Department.
Therefore, CMS is republishing Addenda AA and BB, which were republished on pages 69505 through 69629 and 69630 through 69675 of the December 31, 2009, CY 2010 OPPS/ASC correction document to take into account the updated CY 2010 MPFS information.
Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA-Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)

|  |  | $\left[\begin{array}{c} \infty \\ 0 \\ 0 \\ \vdots \\ \infty \end{array}\right.$ |  | $\mathfrak{c}$ | $8$ |  | $\begin{gathered} 8 \\ 8 \\ 8 \\ 8 \\ \hline 8 \\ \hline \end{gathered}$ |  |  |  |  |  | $\begin{aligned} & 8 \\ & 8 \\ & \hline \\ & \hline \end{aligned}$ |  | $\begin{gathered} 8 \\ \hline 8 \\ \hline \end{gathered}$ | $$ |  |  |  |  | $\stackrel{8}{8}$ |  | $\underset{\sim}{N}$ | $\begin{aligned} & \bar{\infty} \\ & \stackrel{i}{\infty} \end{aligned}$ |  |  |  |  | M |  |  |  |  | $8$ | $8$ | oic |  |  |  |  | $\begin{aligned} & 8 \\ & \hline 8 \\ & \\ & \hline \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\begin{aligned} & \mathrm{y} \\ & \hline \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 1 \begin{array}{l} n \\ \vdots \\ 0 \\ \\ \hline \end{array} \\ & \hline \end{aligned}$ |  |  |  |  | $\begin{aligned} & \underset{\sim}{\infty} \\ & \stackrel{\infty}{M} \\ & \stackrel{\circ}{2} \end{aligned}$ |  |  |  | $\begin{gathered} \frac{m}{7} \\ \stackrel{y}{8} \\ \stackrel{y}{4} \\ \hline \end{gathered}$ |  | $\underset{\sim}{n} \underset{\sim}{c}$ |  |  |  |  |  |  |  | $\begin{aligned} & \pm \\ & \frac{y}{2} \\ & m \\ & m \end{aligned}$ | $\begin{aligned} & 4 \\ & \left.\begin{array}{l} 4 \\ \underset{\sim}{2} \\ \hline \end{array} \right\rvert\, \end{aligned}$ |  |  |  |  |  |  |  | $8$ | $\begin{gathered} \stackrel{e}{e} \\ \stackrel{\rightharpoonup}{\mathrm{~m}} \end{gathered}$ |  | $\begin{aligned} & \frac{9}{8} \\ & 6 \\ & 6 \end{aligned}$ | $\begin{aligned} & \frac{8}{8} \\ & \stackrel{6}{6} \end{aligned}$ |  |  | $\begin{gathered} \frac{\pi}{8} \\ 8 \end{gathered}$ |  |  |
|  | 8 | ¢ | 2 | ¢ | 8 | < | 8 | 8 | \% | y | 2 | < | ¢ | d | 8 | ¢ | ® | d | \% | \% | a 0 | Ő |  | 0 |  | 8 | - | ¢ | d | 8 | \% | d | 88 | c | ¢ | < | d | 2 | d | $8^{2}$ | 40 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 颜 |  |  |  |  | 呂 |  |  |  |  |  |  |
| $\begin{array}{r} 8 \\ 0 \\ \frac{0}{1} 80 \\ \hline 8 \end{array}$ |  | $8$ | $8$ |  | $5 \cdot \frac{0}{5}$ | $\frac{0}{i} \underset{\sim}{\underset{\sim}{5}}$ | $\stackrel{\rightharpoonup}{\rho} \underset{\sim}{s}$ |  | $\frac{9}{5} / \frac{N}{i n}$ | $\stackrel{8}{6} \underset{\sim}{\mathrm{~N}}$ |  | $\frac{2}{2}$ | $\bar{m}$ | $\begin{aligned} & 2 \\ & \\ & \hline \end{aligned}$ |  | $\frac{8}{81} \stackrel{5}{5} \stackrel{5}{9}$ | $\frac{5}{2} \frac{\pi}{2}$ |  | $\begin{aligned} & \frac{8}{8} \\ & \frac{8}{2} \\ & \hline \end{aligned}$ | $\frac{8}{5}$ | $\frac{9}{5}$ | $\frac{8}{5}$ | $\stackrel{N}{5}$ | $\frac{n}{5}$ |  | $8$ |  |  |  |  |  |  |  |  |  | $\begin{aligned} & \text { N్N } \\ & \stackrel{y}{c} \end{aligned}$ |  | $\circ$ $\stackrel{\circ}{2}$ $\stackrel{2}{2}$ |  | $\begin{aligned} & \infty \\ & 0 \\ & 0 \\ & \\ & 0 \end{aligned}$ |  |


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)




Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


|  | $\begin{aligned} & n \\ & \frac{n}{n} \\ & \frac{6}{n} \\ & \hline \end{aligned}$ |  |  |  |  |  |  |  | $\left[\begin{array}{c} \bar{y} \\ \substack{\infty \\ \infty \\ \infty \\ \hline} \end{array}\right.$ |  | $\begin{gathered} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{gathered}$ |  |  |  |  |  |  | $8$ |  | $5{ }_{8}^{8}$ |  |  |  |  |  |  |  | $\underset{6}{9}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0.6 \end{aligned}$ |  | $\begin{aligned} & 9 \\ & \frac{8}{6} \\ & \frac{1}{2} \\ & \hline \end{aligned}$ |  |  | $\begin{gathered} \bar{\sigma} \\ \dot{B} \\ 6 \\ 6 \\ 0 \end{gathered}$ |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | $6$ | $\underset{\sim}{c}$ | $\begin{aligned} & \mathrm{N} \\ & \stackrel{N}{0} \\ & \stackrel{y y y}{c} \end{aligned}$ | $3$ | $\frac{8}{80}$ |  |  | $\begin{aligned} & 4 \\ & \frac{4}{8} \\ & \frac{9}{4} \end{aligned}$ |  |  |  |  |  |  |  |  |  | $0$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $8$ |  |  |  |  |  |  |
|  | 8 | 8 | 2 | 20 | 8 | 8 | \% | 4 | 2 | O | - | ¢ | ¢ | 2 | ¢ | < 2 | 2 | 2 | i | \% | 0 | 0 | O | $\check{\square}$ |  | \% |  | 4 | 8 |  | y |  | O | 2 | ¢ | 4 | y | \% |  | \& | ${ }^{2}{ }^{2}$ |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $\left\lvert\, \begin{aligned} & \frac{0}{2} \\ & \frac{2}{2} \\ & 0 \\ & 0 \\ & 2 \\ & \frac{1}{c} \\ & \frac{c}{c} \end{aligned}\right.$ |  | $\begin{gathered} 9 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{gathered}$ |  |  |  | $\begin{array}{\|l\|} \frac{\pi}{6} \\ \frac{0}{6} \\ \frac{6}{6} \\ 0 \\ 0 \\ \frac{5}{2} \\ \frac{9}{2} \end{array}$ |  |  | Incision of tendon sheath |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $6$ |  |  | $\begin{gathered} 0 \\ \stackrel{0}{6} \\ \underline{\alpha} \end{gathered}$ |  |  |  |
| $\begin{aligned} & 9 \\ & \frac{0}{0} \frac{1}{8} \\ & \frac{1}{8} \end{aligned}$ |  |  |  |  | $\stackrel{y}{\infty}$ |  | $\begin{gathered} \underset{\sim}{0} \\ \underset{\sim}{N} \end{gathered}$ | $3$ | $\begin{aligned} & 8 \\ & 8 \\ & \mathbf{C N} \end{aligned}$ | $\begin{gathered} 8 \\ \hline \end{gathered}$ | $\begin{gathered} 58 \\ 80 \\ 80 \\ 8 \\ \hline \end{gathered}$ | $\stackrel{\substack{0 \\ \\ \hline}}{ }$ | S | + | N/ | ¢ |  | , | 道 |  |  |  |  | 苓 |  |  |  |  |  |  |  |  | 8 |  |  |  |  |  |  | $\frac{9}{5}$ | - |

Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)

Addendum AA-- Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


|  |  |  | $\begin{aligned} & \hat{3} \\ & 0 \\ & 8 \\ & 8 \end{aligned}$ | $\begin{aligned} & 1 \\ & e_{0}^{1} \\ & 8 \end{aligned}$ | $\begin{array}{\|l\|} \hline \\ \hline \\ \dot{8} \\ \hline \\ \hline \end{array}$ | $\begin{aligned} & \hat{e} \\ & \dot{B} \\ & 0 \\ & 0 \end{aligned}$ | $3 \cdot \underset{B}{C}$ |  |  |  |  |  | $\begin{aligned} & 5 \\ & 5 \\ & 8 \\ & 8 \\ & 8 \\ & 8 \\ & 8 \end{aligned}$ | 8 <br> 8 <br> 8 <br> 8 <br> 8 <br> 0 <br> 0 <br> 0 | 8 |  |  |  |  |  |  | $\begin{aligned} & \infty \\ & 0 \\ & 0 \\ & \hline \end{aligned}$ |  |  |  |  |  |  | $\left\{\begin{array}{l} 2 \\ 0 \\ 8 \end{array}\right.$ | $8$ | $\frac{0}{6}$ |  |  | $\stackrel{c}{c}$ |  |  | $\stackrel{C}{6}_{6}^{\infty}$ | $3 \begin{aligned} & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 3 \\ & 5 \\ & \vdots \\ & \hline \end{aligned}$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | $\begin{aligned} & \underset{\sim}{5} \\ & \underset{\sim}{d} \end{aligned}$ | $\underset{\sim}{c}$ |  |  |  |  |  |  |  |  | $\underset{\sim}{\underset{\sim}{c}} \underset{\sim}{\underset{\sim}{2}}$ |  | $\underset{\sim}{c}$ | $\dot{C}$ |  |  |  |  |  |  |  | $\begin{aligned} & 8 \\ & 0 \\ & 0 \\ & 0 \\ & \hline \end{aligned}$ |  |  |  | $\underset{7}{9}$ | $\stackrel{N}{N}$ |  |  |  |  |  |  |  |  |  | $\underset{\dot{8}}{8}$ |  |
|  | 8 | 2 | 8 |  | 2 | 2 | 2 | ¢ | Q | 2 | 12 | 12 | 8 | 8 | 42 | ¢ | 8 | d | \% | 8 | ¢ | 48 | < | ${ }^{1}$ | 8 | d | ¢ | 2 | 2 | 2 | - | ¢ | 8 | ¢ | < |  | 2 |  | 2 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | - |  |  | > |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  | Hand tendon reconstruction |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $18$ |  |  | 品 |  |  |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & 8 \\ & 08 \\ & 18 \\ & 18 \\ & 8 \end{aligned}$ |  |  |  |  |  | $$ |  |  | $\begin{gathered} 8 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{gathered}$ | $\begin{aligned} & 0 \\ & 8 \\ & 8 \end{aligned} \mathbf{o}$ |  | $\stackrel{0}{6}$ |  |  |  |  |  | - |  |  |  | 8 |  |  |  |  |  |  |  |  |  |  |  |  | - |  |  |  | \% |  |

Addendum AA－Final ASC Covered Surgical Procedures for CY 2010 （Including Surgical Procedures for Which
Payment is Packaged）


|  |  | $\begin{aligned} & \hat{1} \\ & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $5 \begin{gathered} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{gathered}$ |  |  |  |  |  |  |  |  |  | $\begin{aligned} & 2 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & \hline \end{aligned}$ |  |  |  |  |  |  |  |  |  | O |  |  | $6$ |  |  |  |  |  |  |  |  | $\begin{aligned} & 18 \\ & 3 \\ & 6 \\ & 6 \end{aligned}$ | $\stackrel{8}{8} 8 \stackrel{y}{8}$ |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\begin{gathered} \bar{N} \\ \\ \end{gathered}$ | $\stackrel{8}{8}$ | $\begin{array}{l\|l\|l} 8 \\ 8 & 0 \\ 8 \\ 8 \\ \hline \end{array}$ |  |  |  |  | $\dot{i}$ |  |  |  |  | $\underset{\sim}{\mathrm{S}} \underset{\mathrm{~N}}{\mathrm{~m}}$ | $\begin{aligned} & m \\ & \substack{m \\ n \\ n \\ \hline} \end{aligned}$ |  | $\begin{aligned} & { }_{2} \\ & \mathrm{P} \\ & \mathrm{O} \end{aligned}$ |  |  |  | $\stackrel{N}{N}$ |  | $\stackrel{\circ}{\circ}$ |  |  |  |  |  | $\begin{gathered} \infty \\ 0 \\ c \\ \end{gathered}$ |  |  |  |  |  |  |  |  |  |  |  | $\stackrel{\square}{\square}$ |
|  | \％ |  | 2 | ${ }^{1}$ | \％ | 2 | 28 | 8 | ＜ | d | 8 | ${ }^{2}$ | 28 | 0 |  | 0 | 2 | O | O | ¢ | 88 | ¢ | 8 | 8 |  | d | d | － | d |  | $\bar{z}$ |  | 8 | 8 |  | ${ }^{2}$ | 8 | ＜ | 2 | 2 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $\bar{z}$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  | － |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | Amputation of finger/thumb |  |  |  |  |  | 5 <br> 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | cr |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & 8 \\ & 0 \\ & 0 \\ & \hline 18 \\ & \hline 8 \end{aligned}$ |  | $\begin{aligned} & \circ \\ & \hline 8 \\ & \hline 0 \\ & \hline \end{aligned}$ | $\stackrel{y}{s} \stackrel{5}{5}$ |  | -8্ত্ণ | $\underset{\substack{8 \\ \hline \multirow{4}{*}{\hline \\ \hline}\\ \hline \\ \hline}}{ }$ | $\frac{3}{8}$ |  | 骨 |  |  | N | 守 | F |  |  |  |  | 等 |  | 8 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 아아아 |  |  |  | － |

Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA -. Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA－Final ASC Covered Surgical Procedures for CY 2010 （Including Surgical Procedures for Which
Payment is Packaged）

|  |  | $\begin{aligned} & \infty \\ & \hline 8 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  |  |  | $\begin{gathered} 3 \\ 5 \\ 5 \\ 0 \\ 0 \\ 0 \end{gathered}$ | $\begin{aligned} & 4 \\ & \substack{0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0} \\ & \hline \end{aligned}$ |  |  |  | $\begin{aligned} & 8 \\ & \stackrel{y}{c} \\ & \hline \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \text { Co } \\ & \hline \end{aligned}$ | $\underset{\sim}{\infty}$ |  | $\begin{aligned} & 5 \\ & i \\ & i \\ & 9 \\ & \hline \end{aligned}$ |  |  |  |  |  |  | $\begin{aligned} & 0 \\ & \mathrm{~N} \\ & \mathrm{~N} \\ & \hline \end{aligned}$ |  |  |  | $\begin{gathered} \mathrm{N} \\ \underset{\sim}{N} \end{gathered}$ |  | $\left[\begin{array}{l} 0 \\ 0 \\ 0 \\ 0 \end{array}\right.$ |  |  |  | $\infty$ |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |  |  |  |  |  | $\stackrel{-}{\square}$ | $\stackrel{-}{8}$ |  |  |  |  |  |  | $\stackrel{-}{8}$ | － |  |  |  |  |  |  |  |  |  |  | $\begin{array}{\|c} \stackrel{\rightharpoonup}{5} \\ \mathbf{\infty} \\ \stackrel{\rightharpoonup}{2} \\ \stackrel{1}{2} \end{array}$ |  |  |  |  |  |  | $\stackrel{\leftarrow}{\stackrel{\rightharpoonup}{\infty}}$ |  |  |
|  | ${ }^{2}$ |  | 2 | N | $\stackrel{\sim}{2}$ |  | $\square_{2}^{2}$ | \％ |  |  |  |  | $2^{2}$ |  | ${ }^{2}$ |  |  |  |  | $0^{2}$ |  |  | $\because$ | $\check{2}$ | $2^{2}$ | \％ | 2 | 2 | $¢$ | ¢ | $\stackrel{3}{2}$ | 8 | 2 |  |  | ＜ |  | 2 | ${ }^{2}$ | E |  | 2 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 2 |  | $z$ | 22 | 2 |  | $z z$ | 2 | $z z$ | $z$ | $z \geq$ | 22 | 22 | $2 z$ |  |  | $z$ |  |  | zz | $z$ | $z$ | $z$ | z | 2 | $z$ | $z$ |  | $z$ | $z$ | 2 |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | Application of hip casts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $\begin{aligned} & \text { 菏 } \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0_{0}^{0} \\ & 0 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  |  | $\underset{c}{c}$ |  |  |  |  |  |  |  |
| $\begin{aligned} & 10 \\ & 0 \\ & 0 \\ & \hline 18 \\ & \hline \end{aligned}$ | $\begin{array}{\|c\|} \hline 8 \\ 2 \\ 2 \end{array}$ | $\begin{aligned} & \text { 若 } \\ & \end{aligned}$ | $\mathfrak{B}$ | $\begin{gathered} 9 \\ 8 \\ 8 \\ \hline \end{gathered}$ |  |  |  | $8 \begin{aligned} & 8 \\ & 8 \\ & 8 \\ & \hline \end{aligned}$ |  | $\stackrel{3}{4}$ |  |  |  | $\begin{aligned} & 8 \\ & 8 \\ & \hline \\ & \hline \end{aligned}$ |  | $\frac{10}{8}$ |  |  |  |  | $\begin{array}{l\|l\|l\|l\|l\|l\|l\|} \hline \end{array}$ |  |  | $0$ | $\stackrel{\sim}{9}$ | 㐫 | S | N | $\left\{\begin{array}{l} 8 \\ \substack{2 \\ N} \end{array}\right.$ | \％ |  | $\stackrel{8}{8}$ | $\begin{aligned} & 4 \\ & 8 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{gathered} 8 \\ \hline \\ \hline \end{gathered} 0_{0}^{9}$ |  |  | $\stackrel{\circ}{\ddot{\circ}} \underset{\sim}{\circ}$ |  |  |  | $\begin{array}{c\|c} Q_{0}^{\infty} \\ \hline \end{array}$ |  |




Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA－Final ASC Covered Surgical Procedures for CY 2010 （Including Surgical Procedures for Which
Payment is Packaged）

|  |  |  |  |  |  |  |  | 信 |  |  |  |  |  |  | － | \％ |  |  |  |  |  |  | $\begin{gathered} \bar{N} \\ \stackrel{y}{\infty} \\ \underset{\leftrightarrow}{2} \end{gathered}$ | － | \％ | ${ }^{\circ}$ |  |  |  |  |  | $$ |  | ＋ |  |  | $\stackrel{\text { N }}{ }$ | $\stackrel{\stackrel{3}{6}}{\substack{6 \\ 4 \\ \hline}}$ | $\stackrel{m}{\frac{m}{c}}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  | ＋ |  |  |  |  |  |  |  |  |  |  | － | ¢ | － | O． | O－ | O |  | ¢ |  |  |  |  |  | ＊ |  | \％ | $\underset{\infty}{\infty}$ |  |  | $\stackrel{\square}{5}$ | $\stackrel{\square}{\square}$ |
|  |  | $z$ | 2 |  |  | $\bar{z}$ |  |  |  | d | z | 2 | $z z$ | $2 \times$ |  | V |  | N | 8 |  |  | Y | N |  |  |  |  |  |  |  | \％ | $\bigcirc$ |  | \％ | ล | N |  |  | \＆ |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  | ㄷ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | 2 | 2 |  | 2 | $z>$ |  | $\gg$ | $\bigcirc 2$ | $z$ | $z$ | $z$ | 22 | $z$ | $z z$ |  |  | 22 |  |  |  |  | ＞ |  |  |  |  | $z 2$ |  | 2 |  |  | $z$ | $z$ | $z$ |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & 9 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ |  | $\stackrel{N}{2}$ | $\begin{gathered} =0 \\ 0 \\ 0 \\ \hline \end{gathered}$ | $\left\|\begin{array}{l} 0 \\ \vdots \\ 0 \\ \hline \end{array}\right\|$ |  | $\begin{gathered} \mathrm{d} \\ \mathrm{c} \end{gathered}$ |  |  |  |  |  | $18$ |  | Mis |  | $\begin{aligned} & 9 \\ & \substack{3 \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline} \\ & \hline \end{aligned}$ | 京 | $\begin{aligned} 8 \\ 5 \\ 0 \\ 0 \\ \hline 0 \\ \hline \end{aligned}$ | $\begin{gathered} 6 \\ \hline \end{gathered}$ |  |  |  | 黄 |  |  |  |  | d |  |  | $\begin{aligned} & -\stackrel{F}{8} \\ & \hline 0 \end{aligned}$ | $3 \begin{aligned} & \overline{4} \\ & \hline \end{aligned}$ | \％ | 蜽 | $\left\|\begin{array}{l} 10 \\ 8 \\ 0 \end{array}\right\|$ | $\stackrel{\bullet}{\square}$ | ¢ |  | － |

Addendum AA－Final ASC Covered Surgical Procedures for CY 2010 （Including Surgical Procedures for Which
Payment is Packaged）



Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)

Addendum AA－Final ASC Covered Surgical Procedures for CY 2010 （Including Surgical Procedures for Which
Payment is Packaged）


|  |  | $\begin{aligned} & \infty \\ & \infty \\ & 0 \\ & 0 \end{aligned}$ | $\left\|\begin{array}{l} \infty \\ 0 \\ 0 \\ 0 \\ 0 \end{array}\right\|$ | $\begin{aligned} & N \\ & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\left\{\begin{array}{l} n \\ 0 \\ \vdots \\ 0 \\ 0 \end{array}\right.$ | $\begin{gathered} N_{2} \\ \hline \\ \hline \\ \hline \end{gathered}$ |  |  |  |  |  |  |  |  |  |  |  | $\frac{18}{\infty}$ | $\begin{aligned} & 80 \\ & \frac{8}{6} \\ & \frac{0}{6} \\ & \hline 8 \end{aligned}$ |  |  |  |  |  |  |  | $\begin{aligned} \substack{\infty \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline} \end{aligned}$ |  |  |  |  |  | $\left.\begin{aligned} & \dot{4} \\ & 0 \\ & 0 \\ & 0 \\ & 8 \end{aligned} \right\rvert\,$ |  |  |  | $e_{0}^{2}$ |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{aligned} & 8 \\ & \frac{2}{2} \\ & -1 \end{aligned}$ | $\begin{aligned} & \circ \\ & 0 \\ & 8 \\ & 8 \\ & \end{aligned}$ | $\left(\begin{array}{l} \mathbf{N} \\ \vdots \\ 8 \\ \hline \end{array}\right.$ | $\begin{gathered} \underset{\sim}{2} \\ \stackrel{y}{c} \\ \dot{\sim} \end{gathered}$ | $\begin{aligned} & \text { N } \\ & \text { N } \\ & \text { Nin } \end{aligned}$ |  |  |  |  |  |  |  |  | $\stackrel{y}{4}$ |  |  |  |  | $\mathfrak{c}$ |  |  |  |  |  |  |  | $\begin{gathered} \underset{8}{3} \\ \hline 8 \\ \hline 8 \\ \hline \end{gathered}$ |  | $8$ | $\begin{aligned} & \text { 导 } \\ & \stackrel{y}{c} \end{aligned}$ |  | $\begin{aligned} & \infty \\ & \underset{\infty}{\infty} \\ & \underset{\infty}{\infty} \end{aligned}$ | $\begin{aligned} & \infty \\ & \frac{\infty}{\infty} \\ & \infty \\ & \hline \end{aligned}$ | $\begin{array}{\|c} 4 \\ \stackrel{y}{n} \\ \stackrel{n}{n} \\ \hline \end{array}$ |  |  | $\begin{aligned} & \text { Cu} \\ & \substack{0} \\ & \hline 8 \end{aligned}$ |  |  |  |
|  | N | \％ | 2 | 8 | 2 | 2 | 8 | 8 | ¢ | ¢ 2 | 2 | 2 | ¢ 2 | 2 | 2 | 2 | 8 | 8 | 2 | 4 | $\bar{z}$ |  | $\frac{5}{2}$ |  | 8 | ¢ | 28 | 2 | 2 | \％ |  | \％ | \％ | \％ |  | 8 | d |  | $\mathrm{S}^{2}$ | $2^{2}$ |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 2 |  |  |  |  |  |  | －＞ |  | $>$ | $>$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 응 | － |  |  |  |  |  |  |  |  |
| $\begin{aligned} & 3 \\ & 0 \\ & 0 \\ & 5 \\ & 1 \end{aligned}$ |  | 扁若 | $\begin{aligned} & 8 \\ & 8 \\ & 0 \\ & 8 \end{aligned}$ | $\begin{array}{r} \infty \\ \hline 8 \\ 0 \\ 0 \\ \hline \end{array}$ | $3 \begin{aligned} & 8 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ |  |  |  |  | N్ల్ల్ల్ల్ల్ల్ల | ${ }_{8}^{8}$ |  |  |  |  | N |  |  |  |  |  |  |  |  |  | 8 |  | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & \hline 8 \end{aligned}$ | 8 | \％ | 道 | N |  | $8$ |  |  |  |  | $\begin{aligned} & 8 \\ & 0 \\ & 0 \\ & \hline 0 \end{aligned}$ | （1） |

Addendum AA- Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


|  |  |  |  | $\begin{aligned} & 0 \\ & 2 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{gathered} N \\ N \\ \stackrel{\rightharpoonup}{8} \\ \hline 8 \end{gathered}$ | $\begin{aligned} & N \\ & N_{8} \\ & 0 \end{aligned}$ | $\begin{aligned} & N \\ & \hat{N} \\ & 8 \\ & Q_{2} \end{aligned}$ | $\begin{aligned} & N \\ & 8 \\ & 8 \\ & 8 \\ & 2 \end{aligned}$ |  |  |  |  |  | $\left\{\begin{array}{l} \infty \\ \infty \\ \infty \\ 0 \\ 0 \end{array}\right.$ | $\left\{\begin{array}{l} 1 \\ 0 \\ 8 \\ 8 \\ 0 \end{array}\right.$ | $\|0\|$ |  |  | $\begin{array}{c\|c} 8 \\ \hline 8 & 6 \\ 5 & 9 \\ 5 & 8 \\ 8 \end{array}$ |  |  |  |  |  | 告 |  |  | $\left\lvert\, \begin{gathered} \mathrm{y} \\ \mathrm{U} \\ \mathrm{U} \\ \hline \end{gathered}\right.$ |  |  |  | $\left\lvert\, \begin{aligned} & \infty \\ & \infty \\ & \infty \\ & \infty \\ & \infty \end{aligned}\right.$ |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\left\lvert\, \begin{aligned} & Q_{0} \\ & \begin{array}{c} 0 \\ \vdots \\ \hline \end{array} \end{aligned}\right.$ |  | $\begin{aligned} & \hat{N} \\ & 8 \\ & \underset{N}{2} \end{aligned}$ | $\begin{aligned} & \circ \\ & \frac{0}{2} \\ & \stackrel{3}{c} \end{aligned}$ | $\begin{aligned} & 8 \\ & \frac{8}{5} \\ & \frac{2}{2} \\ & \hline \end{aligned}$ | $\frac{8}{9} \frac{0}{2}$ | $\begin{array}{ll} \infty \\ \frac{0}{5} \\ 2 \\ 2 \\ 2 \end{array}$ | $\begin{aligned} & \frac{0}{n} \\ & \frac{1}{4} \\ & \frac{1}{4} \\ & \hline \end{aligned}$ |  |  |  |  | $$ |  | $\begin{gathered} 0 \\ \hline \end{gathered}$ | - |  |  |  |  | $\stackrel{y}{4}$ |  |  | - |  | $\stackrel{\&}{\infty}$ | $\stackrel{c}{8} \underset{\sim}{\infty}$ | $\stackrel{\infty}{\infty} \underset{\infty}{\infty}$ | $\begin{aligned} & \infty \\ & \\ & \infty \end{aligned}$ | $\bigcirc$ | $\begin{aligned} & 4 \\ & \hline \\ & \hline \\ & \hline \end{aligned}$ | $\begin{aligned} & 2 \\ & k \\ & \infty \\ & \infty \end{aligned}$ | $\underset{\infty}{N}$ | N | $\begin{aligned} & \stackrel{8}{8} \\ & \stackrel{\circ}{\circ} \end{aligned}$ | $\begin{gathered} \infty \\ \infty \\ \infty \end{gathered}$ |  |  |  |
|  |  | 2 | \% |  | ¢ | d |  |  |  | ¢ | ${ }^{2}$ | 4 | 8 | E | 2 | 2 | 8 |  |  |  | < | - |  | 4 | \& | 48 | 2 | 2 | \% | 2 | \% | 2 | \% | $\underset{4}{2}$ | \% | ¢ | \% |  | < | त2 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & \stackrel{\rightharpoonup}{2} \\ & \frac{2}{2} \\ & \stackrel{0}{0} \\ & \stackrel{0}{2} \\ & \stackrel{\rightharpoonup}{5} \\ & \stackrel{\rightharpoonup}{5} \\ & \hline \end{aligned}$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $5$ |  |  |  |  |  |  |  | Esophagus endoscopy |  |  |  |  |  |  |  |  |  |
| $1 \begin{aligned} & 8 \\ & \frac{0}{2} \\ & \frac{1}{8} \\ & 8 \end{aligned}$ |  |  | $\begin{gathered} 8 \\ 0 \\ 0 \\ 9 \end{gathered}$ | $\begin{array}{r} \bar{\alpha} \\ \substack{8 \\ \hline \\ \hline} \end{array}$ |  | $\begin{gathered} 0 \\ 0 \\ \vdots \\ 7 \end{gathered}$ |  | $\begin{array}{\|c\|} \bar{\sim} \\ \underset{\sim}{2} \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & \left.\begin{array}{c} 0 \\ \underset{\substack{2}}{ } \end{array}\right\} \\ & \vdots \end{aligned}$ |  |  |  |  | $$ |  |  |  |  |  |  |  |  |  |  | $\underset{\sim}{\tilde{q}}$ |  |  | $\begin{gathered} 8 \\ \mathbf{0} \\ \mathbf{y} \end{gathered}$ | - | $\begin{aligned} & 9 \\ & \vdots \\ & \text { 等 } \end{aligned}$ | $\underset{\text { - }}{\text { ¢ }}$ | $\begin{aligned} & \frac{0}{2} \\ & N_{\mathrm{z}}^{2} \end{aligned}$ | $\begin{aligned} & 2 \\ & \tilde{N} \\ & \tilde{y} \end{aligned}$ | $\mathrm{N}_{2}$ |  |  | ${ }^{\mathrm{N}}$ |  |  |  |

Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


4914 M


Addendum AA -- Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)

Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)



Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)
Payment Is

Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA－Final ASC Covered Surgical Procedures for CY 2010 （Including Surgical Procedures for Which
Payment is Packaged）


|  |  |  |  | $\begin{gathered} n \\ 0 \\ \vdots \\ \vdots \\ \vdots \end{gathered}$ |  |  | ${ }_{8}^{9}{ }_{8}^{9}$ | $\begin{aligned} & \infty \\ & \frac{\infty}{2} \\ & \underset{y}{\infty} \\ & \hline \end{aligned}$ |  |  | $\begin{aligned} & 9 \\ & 0 \\ & 0 \\ & 6 \\ & 6 \\ & \hline 6 \end{aligned}$ | $\begin{aligned} & 9 \\ & 0 \\ & 2 \\ & m \\ & \hline 6 \end{aligned}$ |  |  | 0 0 0 0 0 | $\begin{gathered} 2 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ \hline \end{gathered}$ | $\left\lvert\, \begin{gathered} A_{2} \\ d \\ d \\ d \end{gathered}\right.$ |  | $\begin{aligned} & \mathscr{\circ} \\ & \stackrel{\omega}{\alpha} \\ & =1 \end{aligned}$ | $\begin{aligned} & { }_{c} \\ & \text { a } \end{aligned}$ | $\begin{aligned} & \mathrm{N} \\ & \mathrm{~N} \\ & \hline \mathbf{0} \end{aligned}$ |  | $\begin{aligned} & N \\ & \vdots \\ & 0 \\ & 0 \end{aligned}$ |  | $\begin{aligned} & \text { A } \\ & \text { N } \\ & \text { Non } \end{aligned}$ |  |  | $?$ |  | $\mathfrak{g}$ | $\begin{aligned} & \text { l} \\ & 0 \\ & \hline \end{aligned}$ | $\left\lvert\, \begin{aligned} & \mathbf{4} \\ & 0 \\ & 0 \\ & 0 \end{aligned}\right.$ |  | $\begin{aligned} & 4 \\ & \hline \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & \infty \end{aligned}$ | $\begin{gathered} \text { Cuck } \end{gathered}$ |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | $\begin{aligned} & \left.\begin{array}{l} 0 \\ \vdots \\ \vdots \\ \underset{\sim}{2} \end{array}\right\} \\ & \hline \end{aligned}$ |  |  | $\begin{aligned} & 9 \\ & 0 \\ & 0 \\ & \vdots \\ & 0 \end{aligned}$ |  |  | $\stackrel{\stackrel{N}{N}}{\stackrel{\rightharpoonup}{\dot{\circ}}} \mid$ | $\begin{gathered} c \\ s \\ s \\ s \end{gathered}$ | $\begin{gathered} \underset{y}{c} \\ \underset{c}{c} \\ i \end{gathered}$ | $\begin{gathered} \mathrm{y} \\ \mathrm{y} \\ \mathrm{~m} \end{gathered}$ | $\begin{array}{\|c} 8 \\ 5 \\ 80 \end{array}$ |  | $\begin{aligned} & 2 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{gathered} \text { y } \\ \stackrel{y}{c} \\ \stackrel{y}{c} \end{gathered}$ | $\begin{aligned} & \bar{o} \\ & \underset{x}{y} \\ & \underset{F}{2} \end{aligned}$ |  | $\begin{gathered} N \\ \\ \end{gathered}$ |  | $\begin{aligned} & \text { y } \\ & 0 \\ & \infty \\ & \infty \\ & \infty \end{aligned}$ | 谷 |  |  |  |  |  |  |  | － | －8 |  |  |  | $\stackrel{\infty}{\infty}$ |  |  |  |  | $\stackrel{N}{N}$ |
|  | 8 | ＜ | 2 |  | \％ | 2 | \％ | O | O | c | 8 | 2 | 8 | 2 | 2 | \％ |  | 0 | $<$ | d | d | z | 2 | \％ | － | \％ | 2 | $\stackrel{2}{2}$ | 2 | $\bigcirc$ |  | 8 |  | 8 | \％ |  | 2 |  |  | O |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $\frac{9}{9}$ <br> $\frac{2}{6}$ <br> 0 <br> 2 <br> 2 <br> 2 <br> $\frac{8}{8}$ <br> $\frac{8}{2}$ <br> 2 |  |  |  | sn/m snquopume wopqesue.1. | 3 <br> 3 <br> 3 <br> 0 <br> 8 <br> 0 <br> 0 <br> 0 |  | － |  | $\begin{gathered} 0 \\ 6 \\ 5 \\ 0 \\ 0 \\ 0 \\ 0 \\ \frac{0}{2} \\ 0 \\ 0 \end{gathered}$ |  |  |  | $\underset{\substack{6 \\ \\ \hline}}{2}$ |  |
| $\begin{aligned} & 0 \\ & 8 \\ & 0 \\ & \hline 1 \\ & \hline \end{aligned}$ | $\left[\begin{array}{l} 0 \\ 0 \\ 0 \\ 0 \end{array}\right.$ | $3 \begin{aligned} & 8 \\ & 8 \\ & 8 \\ & 8 \\ & 8 \end{aligned}$ | $\begin{aligned} & 8 \\ & 8 \\ & 8 \\ & 0 \end{aligned}$ | ie | $\begin{array}{\|c} 8 \\ 88 \\ 88 \end{array}$ | $\begin{aligned} & 8 \\ & 0 \\ & 8 \\ & 8 \end{aligned}$ | ${ }_{0}^{0} 8$ |  | $\left.\begin{array}{\|l\|} \hline 10 \\ \hline 8 \\ \hline 8 \end{array} \right\rvert\,$ |  | $\left\lvert\, \begin{array}{\|c\|} \hline \end{array}\right.$ | $\left\lvert\, \begin{gathered} 0 \\ 8 \\ 8 \\ 0 \end{gathered}\right.$ | $\left\|\begin{array}{l} 8 \\ 0 \\ 8 \\ 8 \end{array}\right\|$ |  |  |  | $\left\|\begin{array}{l} 8 \\ 0 \\ 0 \\ 0 \\ 0 \end{array}\right\|$ |  | － |  | － | － | $\begin{aligned} & 0 \\ & 0 \\ & 8 \\ & 8 \end{aligned}$ | $18$ | 8 | $\stackrel{5}{8}$ |  |  | 発 | $38$ | \％ |  |  | 号 | 硣 |  |  |  |  |  |

Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA -- Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)

|  |  | $\begin{aligned} & \infty \\ & 8 \\ & 0 \\ & 0 \\ & \infty \\ & \infty \end{aligned}$ |  |  | $\left\lvert\, \begin{aligned} & \infty \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & \tilde{m} \end{aligned}\right.$ | $\left\|\begin{array}{l} 8 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{array}\right\|$ |  |  | $\left[\begin{array}{l} 0 \\ 0 \\ 0 \\ 8 \\ 8 \\ 8 \\ 8 \end{array}\right.$ | $\begin{aligned} & \overline{6} \\ & 0 \\ & = \\ & 8 \\ & 0 \end{aligned}$ |  | $\begin{aligned} & \infty \\ & \stackrel{0}{2} \\ & \stackrel{N}{\infty} \\ & \stackrel{\infty}{n} \end{aligned}$ |  | $\begin{aligned} & N \\ & \mathrm{~N} \\ & \mathrm{~N} \\ & \mathrm{~N} \end{aligned}$ | N 8 8 8 8 |  |  |  | $\begin{aligned} & 8 \\ & 0 \\ & \vdots \\ & 8 \\ & 8 \end{aligned}$ | $\begin{gathered} 8 \\ \dot{8} \\ \underset{8}{8} \end{gathered}$ |  |  | $\begin{aligned} & 8 \\ & 8 \\ & 0 \\ & 8 \\ & 8 \end{aligned}$ |  |  |  |  |  | $\begin{array}{\|c} 8 \\ 0 \\ 8 \\ 8 \\ \hline 0.0 \end{array}$ |  |  | W |  |  |  |  | 荷 |  |  | $\begin{aligned} & \sigma_{0}= \\ & \hline \\ & \hline \\ & \hline \end{aligned}$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{aligned} & \infty \\ & 8 \\ & 8 \\ & 0 \end{aligned}$ |  |  | $\left\{\begin{array}{l} 0 \\ 0 \\ 0 \\ i \end{array}\right.$ | $\begin{aligned} & \bar{y} \\ & \infty \\ & \infty \\ & \infty \\ & \infty \end{aligned}$ | 莒 |  |  | $\begin{aligned} & \square \\ & \vdots \\ & \vdots \\ & \vdots \\ & \vdots \\ & \hline \end{aligned}$ | $\mathfrak{c}$ | $\begin{aligned} & 0 \\ & \underset{8}{8} \\ & \underset{\sim}{2} \end{aligned}$ | $\begin{aligned} & \infty \\ & \stackrel{0}{3} \\ & \stackrel{0}{5} \\ & \hline \end{aligned}$ |  | $\begin{array}{\|l} \dot{8} \\ \hline 8 \\ \dot{H} \\ \dot{H} \end{array}$ | $\left[\begin{array}{l} \infty \\ \infty \\ \infty \\ \hline \end{array}\right.$ |  | $\begin{aligned} & \mathbb{Z} \\ & 0 \\ & \vdots \\ & \underset{N}{N} \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \text { ry } \\ & \text { ma } \\ & \stackrel{y}{c} \end{aligned}$ | $\begin{gathered} 9 \\ \underset{\sim}{9} \\ 3 \end{gathered}$ |  |  |  |  |  |  |  |  | 8 |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | 2 | $4{ }^{1}$ | 온 | $\sim$ | $\stackrel{\square}{5}$ | - | $\stackrel{\infty}{\square}$ |  | W | $\underline{\sim}$ | $\stackrel{\infty}{\square}$ | 옥 | 2 | 온 | 2 | 2 | 2 | 8 | 2 | n | ¢ | ¢ |  | < | ¢ ${ }^{1}$ |  | \% |  |  | 2 | 0 |  | \% | \% | \% |  |  | 2 | 28 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | $\gg$ | $>2$ | $z$ | 2 | 22 | 2 | 2 | $z$ |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & \frac{2}{2} \\ & \frac{2}{2} \\ & \frac{0}{0} \\ & \frac{0}{6} \\ & \frac{2}{5} \\ & \hline \end{aligned}$ |  |  |  |  |  |  |  |  |  |  |  |  | Implant neuroelectrades |  |  |  |  |  |  |  |  |  | osnuw we.1xe 'eneu रansea |  |  |  |  |  |  |  |  |  | Chemodenerv eccrine glands |  |  |  |  |  |  |  |  |
| Bo |  | $\stackrel{\rightharpoonup}{4}$ | $\begin{aligned} & 8 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | de | $\begin{aligned} & 0 \\ & 8 \\ & 8 \\ & 8 \\ & \hline \end{aligned}$ | $\left\lvert\, \begin{aligned} & 8 \\ & 8 \\ & 8 \end{aligned}\right.$ | $\begin{aligned} & 8 \\ & 8 \\ & 8 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 8 \\ & 0 \\ & 6 \\ & 6 \\ & \hline \end{aligned}$ | $\left[\begin{array}{l} 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{array}\right.$ |  | $\begin{aligned} & 5 \\ & 5 \\ & 6 \end{aligned}$ | $\begin{aligned} & \hat{6} \\ & \hline 8 \end{aligned}$ | $5$ | $\left\lvert\, \begin{gathered} \overline{0} \\ \stackrel{0}{0} \\ \hline \end{gathered}\right.$ | $\left\{\begin{array}{l} n \\ 0 \\ 0 \\ \hline \end{array}\right.$ | $88$ | $\left\|\begin{array}{l} 2 \\ 0 \\ 0 \\ 0 \end{array}\right\|$ |  |  | ( | ¢ | ¢ |  | $\begin{array}{\|c} 0 \\ \hline \end{array}$ |  |  | $\begin{aligned} & 0 \\ & \hline 0 \\ & \hline \\ & \hline \end{aligned}$ |  | + |  |  | $$ | $\begin{aligned} & \left.\begin{array}{l} 3 \\ 0 \\ 0 \\ \hline \end{array} \right\rvert\, \end{aligned}$ | $\begin{aligned} & \text { e} \\ & \hline \end{aligned}$ | $\left\{\begin{array}{l} \bar{\infty} \\ 0 \\ \hline \end{array}\right.$ | $\begin{aligned} & 8 \\ & 0 \\ & 0 \\ & \hline \end{aligned}$ | $G$ |  |  |  |  |

Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


Addendum AA - Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which
Payment is Packaged)


 NOTE 1: The Medicare program payment is 80 percent of the total payment amount and bencticiary coinsurance is 20 percent of the
total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is total payment amount, except for screening flexible sigmo.
75 percent and the beneficiary coinsurance is 25 percent.
NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
standard rate setting methodoloy and dhe MPS. Under current law, the MPS payment rates will have a negative update for CY
2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

| Addendum AA -- Final ASC Covered Surgical Procedures for CY 2010 (Including Surgical Procedures for Which Payment is Packaged) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS Code | Short Descriptor | Subject To Multiple Procedure Discounting | CY 2010 Comment Indicator | CY 2010 <br> Payment <br> Indicator | CY 2010 Third Year Payment Weight | $\begin{aligned} & \text { CY } 2010 \\ & \text { Third Year } \\ & \text { Transition } \\ & \text { Payment } \end{aligned}$ |
| NOTE 2: Payment indicators for "office-based" procedures (P2, P3) are based on a comparison of the final rates according to the ASC standard ratesetting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CY 2010. For a discussion of those rates, we reter readers to the CY 2010 MPFS final rule, as corrected. |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| *: Asterisked codes(") indicate that the procedure's "office-based," designation is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available. |  |  |  |  |  |  |



[^0]| Addendum BB - Final ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2010 <br> Ancillary Services for Whinch Pluding |
| :--- |

[^1]

[^2]NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the finnal rates according to the ASC
standard rate setting methoodology and the MPFS. Under current taw, the MPFS payment rates will have a negative update for CY
2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

| Addendum BB -- Final ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2010 (Including Ancillary Services for Which Payment is Packaged) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS Code | Short Descriptor | CY 2010 Indicator | CY 2010 Indicator | CY 2010 Third Year Transition Payment Weight | $\begin{aligned} & \text { CY } 2010 \text { Third } \\ & \text { Year Transition } \\ & \text { Payment } \end{aligned}$ |
| 72074 | $x$-ray exam of thoracic spine | CH | z3 |  | \$24.41 |
| 72080 | $x$-ray exam of trunk spine |  | 23 |  | \$17.60 |
| 72090 | $x$-ray exam off trunk spine |  | 23 |  | \$24.13 |
| 72100 | $x$-ray exam of lower spine |  | Z3 |  | \$20.44 |
| 72110 | X-ray exam of lower spine |  | 23 |  | \$28.10 |
| 72114 | $x$-ray exam of lower spine | CH | Z3 |  | \$39.17 |
| 72120 | X-ray exam of lower spine |  | 23 |  | \$27.82 |
| 72125 | Ct neck spine wo dye |  | 22 | 2.7687 | \$115.93 |
| 72126 | Ct neck spine w/dye |  | 22 | 4.2158 | \$176.53 |
| 72127 | Ct neck spine w/o \& w/dye |  | 22 | 4.7337 | \$198.21 |
| 72128 | Ct chest spine w/o dye |  | 22 | 2.7687 | \$115.93 |
| 72129 | Ct chest spine w/dye |  | Z2 | 4.2158 | \$176.53 |
| 72130 | Ct chest spine w/o \& widye |  | 22 | 4.7337 | \$198.21 |
| 72131 | Ct lumbar spine w/o dye |  | Z2 | 2.7687 | \$115.93 |
| 72132 | Ct lumbar spine widye |  | Z2 | 4.2158 | \$176.53 |
| 72133 | Ct lumbar spine w/o \& widye |  | 22 | 4.7337 | \$198.21 |
| 72141 | Mri neck spine w/o dye |  | Z2 | 4.961 | \$207.73 |
| 72142 | Mri neck spine w/dye |  | z2 | 6.0177 | \$251.98 |
| 72146 | Mric chest spine wio dye |  | z2 | 4.961 | \$207.73 |
| 72147 | Mri chest spine w/dye |  | z2 | 6.0177 | \$251.98 |
| 72148 | Mrilumbar spine wio dye |  | 22 | 4.961 | \$207.73 |
| 72149 | Mri lumbar spine widye |  | 22 | 6.0177 | \$251.98 |
| 72156 | Mrineck spine w/o \& widye |  | 22 | 7.5993 | \$318.21 |
| 72157 | Mric chest spine w/o \& w/dye |  | 22 | 7.5993 | \$318.21 |
| 72158 | Mri lumbar spine w/o \& w/dye |  | Z2 | 7.5993 | \$318.21 |
| 72170 | $x$-ray exam of pelvis |  | Z3 |  | \$12.77 |
| 72190 | $x$-ray exam of pelvis | CH | Z3 |  | \$21.29 |
| 72191 | Ct angiograph pelv w/o\&w/dye |  | Z2 | 4.8324 | \$202.35 |
| 72192 | Ct pelvis w/o dye |  | z2 | 2.7687 | \$115.93 |
| 72993 | Ct pelvis w/dye |  | 72 | 4.2158 | \$176.53 |
| 72194 | Ct pelvis w/o \& widye |  | Z2 | 4.7337 | \$198.21 |
| 72195 | Mripelvis w/o dye |  | 22 | 4.961 | \$207.73 |
| 72196 | Mripelvis w/dye |  | 22 | 6.0177 | \$251.98 |
| 72197 | Mri pelvis w/o \& w/dye |  | Z2 | 7.5993 | \$318.21 |
| 72200 | $x$-ray exam sacroiliac joints |  | 23 |  | \$15.05 |
| 72202 | $X$-ray exam sacrailiac joints |  | Z3 |  | \$18.17 |
| 72220 | X-ray exam of tailione |  | 23 |  | \$14.76 |
| 72240 | Contrast x-ray of neck spine |  | N1 |  |  |

[^3]

[^4]| HCPCS Code | Short Descriptor | CY 2010 Comment Indicator | $\begin{aligned} & \text { CY } 2010 \\ & \text { Payment } \\ & \text { indicator } \end{aligned}$ | $\begin{aligned} & \text { CY } 2010 \text { Third Year } \\ & \text { Transition Payment } \\ & \text { Weight } \end{aligned}$ | CY 2010 Third Year Transition Payment |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 73520 | $x$-ray exam of hips |  | Z3 |  | \$19.30 |
| 73525 | Contrast $x$-ray of hip |  | N1 |  |  |
| 73530 | $x$-ray exam of hip |  | N1 |  |  |
| 73540 | $x$-ray exam of pelvis \& hips |  | Z3 |  | \$20.44 |
| 73542 | --ray exam, sacroiltac joint |  | N1 |  |  |
| 73550 | $x$-tay exam of thigh |  | 23 |  | \$13.91 |
| 73560 | X-ray exam of knee, 1 or 2 |  | z3 |  | \$14.76 |
| 73562 | X-ray exam of knee, 3 |  | 23 |  | \$18.45 |
| 73564 | X-ray exam, knee, 4 or more |  | 23 |  | \$21.29 |
| 73565 | $X$-ray exam of knees |  | z3 |  | \$16.46 |
| 73580 | Contrast $x$-ray of knee joint |  | N1 |  |  |
| 73590 | $X$-ray exam oflower leg |  | z3 |  | \$13.63 |
| 73592 | $X$-ray exam of leg, infant |  | 23 |  | \$15.33 |
| 73600 | $x$-ray exam of ankle |  | Z3 |  | \$14.19 |
| 73610 | $x$-ray exam of ankle |  | Z3 |  | \$16.75 |
| 73615 | Contrast $x$-ray of ankie |  | Ni |  |  |
| 73620 | $x$-ray exam of foot |  | 23 |  | \$13.63 |
| 73630 | X-ray exam of foot |  | 23 |  | \$15.46 |
| 73650 | X-ray exam of heel |  | 23 |  | \$13.91 |
| 73660 | Xray exam of toe(s) |  | 23 |  | \$15.61 |
| 73700 | Cl lower extremity wiodye |  | 22 | 2.7687 | \$115.93 |
| 73701 | Ct lower extremity w/dye |  | 22 | 4.2158 | \$176.53 |
| 73702 | Cllwr extremity w/oswidye |  | z2 | 4.7337 | \$198.21 |
| 73706 | Ctangio lwr ext w/oswidye |  | 22 | 4.8324 | \$202.35 |
| 73718 | Mri lower extremity w/o dye |  | z2 | 4.961 | \$207.73 |
| 73719 | Mril lower extremity w/dye |  | z2 | 6.0177 | \$251.98 |
| 73720 | Mril l / extremity W/o8w/dye |  | 22 | 7.5993 | \$318.21 |
| 73721 | Mrijut of lwr extre w/o dye |  | z2 | 4.961 | \$207.73 |
| 73722 | Mrij joint of wr extr w/dye |  | 22 | 6.0177 | \$251.98 |
| 73723 | Mri joint twr extr w/osw/dye |  | 22 | 7.5993 | \$318.21 |
| 74000 | $x$-ray exam of abdomen |  | 23 |  | \$11.92 |
| 74010 | $X$-ray examo of abdomen |  | 23 |  | \$19.02 |
| 74020 | $x$-ray exam of abdomen |  | 23 |  | \$19.30 |
| 74022 | X-ray exam series, abdomen |  | Z3 |  | \$23.28 |
| 74150 | Ct abdomen w/o dye |  | 22 | 2.7687 | \$115.93 |
| 74160 | Ca abdomen w/dye |  | Z2 | 4.2158 | \$176.53 |
| 74170 | Ct abdomen w/o \& widye |  | 22 | 4.7337 | \$198.21 |
| 74175 | Ctangio abdom w/o \& w/dye |  | 22 | 4.8324 | \$202.35 |

[^5] NOTE 1: The Medicare programu payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS paymen
2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^6]

[^7]NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
standard rate setting methoodology and the MPFS. Under current taw, the MPFS payment rates will have a negative update for CY
2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

| Addendum BB -. Final ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2010 (Including Ancillary Services for Which Payment is Packaged) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS Code | Short Descriptor | CY 2010 Comment Indicator | CY 2010 Payment indicator | CY 2010 Third Year Transition Payment Weight | CY 2010 Third Year Transition Payment |
| 75891 | Vein $x$-ray, liver |  | N1 |  |  |
| 75893 | Venous sampling by catheter |  | N1 |  |  |
| 75894 | X-rays, transcath therapy |  | N1 |  |  |
| 75896 | $x$-rays, transcath therapy |  | N1 |  |  |
| 75898 | Follow-up angiography |  | N1 |  |  |
| 75901 | Remove cva device obstruct |  | N1 |  |  |
| 75902 | Remove cva lumen obstruct |  | N1 |  |  |
| 75940 | X-ray placement, vein fiter |  | N1 |  |  |
| 75945 | Intravascular us |  | N1 |  |  |
| 75946 | Intravascular us add-on |  | N1 |  |  |
| 75960 | Transcath iv stent rski |  | N 1 |  |  |
| 75961 | Retrieval, broken catheter |  | N1 |  |  |
| 75962 | Repair arterial blockage |  | N1 |  |  |
| 75964 | Repair artery blockage, each |  | NT |  |  |
| 75966 | Repair arterial blockage |  | N1 |  |  |
| 75968 | Repair artery blockage, each |  | Ni |  |  |
| 75970 | Vascular biopsy |  | N1 |  |  |
| 75978 | $R$ Repair venous blockage |  | N1 |  |  |
| 75980 | Contrast xray exam bile duct |  | N1 |  |  |
| 75982 | Contrast xray exam bile duct |  | N1 |  |  |
| 75984 | Xray control catheter change |  | N1 |  |  |
| 75989 | Abscess drainage under $x$-ray |  | N1 |  |  |
| 75992 | Atherectomy, $x$-ray exam |  | N1 |  |  |
| 75993 | Atherectomy, $x$-ray exam |  | N1 |  |  |
| 75994 | Atherectomy, x-ray exam |  | N1 |  |  |
| 75995 | Atherectomy, x-ray exam |  | N1 |  |  |
| 75996 | Atherectomy, x-ray exam |  | N1 |  |  |
| 76000 | Fliboroscope examination |  | N1 |  |  |
| 76001 | Fluoroscope exam, extensive |  | N1 |  |  |
| 76010 | $x$-ray, nose to rectum |  | 23 |  | \$13.63 |
| 76080 | $x$-ray exam of fistula |  | N1 |  |  |
| 76098 | $X$-ray exam, breast specimen | CH | N1 |  |  |
| 76100 | $X$-ray exam of body section |  | 22 | 1.0678 | \$44.71 |
| 76101 | Complex body section $x$-ray | CH | z3 |  | \$110.71 |
| 76102 | Complex body section $x$-rays |  | 22 | 2.9841 | \$124.95 |
| 76120 | Cine/video x -ays | CH | Z3 |  | \$42.01 |
| 76125 | Cine/video $x$-rays add-on |  | N1 |  |  |
| 76150 | $X$-ray exam, dry process |  | 23 |  | \$14.48 |

[^8]

[^9]| Addendum BB -. Final ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2010 (Including Ancillary Services for Which Payment is Packaged) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS Code | Short Descriptor | CY 2010 Commen | CY 2010 Payment indicator | CY 2010 Third Year Transition Payment Weight | CY 2010 Third Year Transition Payment |
| 76819 | Fetal biophys profil w/o nst |  | 23 |  | \$39.46 |
| 76820 | Umblicical artery echo |  | z3 |  | $\$ 17.88$ |
| 76821 | Middie cerebral artery echo |  | Z2 | 0.8866 | \$37.12 |
| 76825 | Echo exam of fetal heart |  | z3 |  | \$95.95 |
| 76826 | Echo exam of fetal heart |  | 23 |  | \$58.48 |
| 76827 | Echo exam of fetal heart | CH | z3 |  | \$29.24 |
| 76828 | E.cho exam of fetal heart |  | 23 |  | \$16.46 |
| 76830 | Transvaginal us, non-ob |  | Z2 | 1.3809 | \$57.32 |
| 76831 | Echo exam, uterus |  | 23 |  | \$63.87 |
| 76856 | Us exam, pelvic, complete |  | 22 | 1.3809 | \$57.82 |
| 76857 | Us exam, pelvic, , limited |  | z2 | 0.8866 | \$37.12 |
| 76870 | Us exam, scrotum |  | 22 | 1.3809 | \$57.82 |
| 76872 | Us, transrectal |  | z2 | 1.3809 | \$57.82 |
| 76873 | Echograp trans r, pros study |  | Z2 | 1.3809 | \$57.82 |
| 76880 | Us exam, extremity |  | z2 | 1.3809 | \$57.82 |
| 76885 | Us exam infant hips, dynamic |  | z2 | 0.8866 | \$37.12 |
| 76886 | Us exam infant hips, static |  | Z2 | 0.8866 | \$37.12 |
| 76930 | Echo guide, Cardiocentesis |  | N1 |  |  |
| 76932 | Echo guide for heart biopsy |  | N1 |  |  |
| 76936 | Echo guide for attery repair |  | Z2 | 1.5379 | \$64.40 |
| 76937 | Us guide, vascular access |  | N 1 |  |  |
| 76940 | Us guide, tissue ablation |  | N1 |  |  |
| 76941 | Echo guide for transfusion |  | N 1 |  |  |
| 76942 | Echo guide for blopsy |  | N1 |  |  |
| 76945 | Echo guide, villus sampling |  | N1 |  |  |
| 76946 | Echo guide for amniocentesis |  | N1 |  |  |
| 76948 | Echo guide, ova aspliration |  | N1 |  |  |
| 76950 | Echo guldance radiotherapy |  | N1 |  |  |
| 76965 | Echo guidance radiotherapy |  | N1 |  |  |
| 76970 | Ultrasound exam follow-up |  | Z2 | 0.8866 | \$37.12 |
| 76975 | Gl endoscopic ultrasound |  | N1 |  |  |
| 76977 | Us bone density measure |  | 23 |  | \$6.53 |
| 76998 | Us guide, intraop |  | N1 |  |  |
| 76999 | Echo examination procedure |  | 22 | 0.8866 | \$37.12 |
| 77001 | Fluoroguide for vein device |  | N1 |  |  |
| 77002 | Needle localization by xray |  | N1 |  |  |
| 77003 | Fluorogulde for spine inject |  | N1 |  |  |
| 77011 | Ct scan for localization |  | N1 |  |  |

[^10]

[^11]| Addendum BE .-. Final ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2010 (Including Ancillary Services for Which Payment is Packaged) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS Code | Short Descriptor | $\begin{aligned} & \text { CY } 2010 \\ & \text { CYomment } \\ & \text { Indicator } \end{aligned}$ | $\left\lvert\, \begin{aligned} & \text { CY } 2010 \\ & \text { Payment } \\ & \text { Indicator } \end{aligned}\right.$ | $\left\lvert\, \begin{aligned} & \begin{array}{l} \text { Cras } 2010 \text { Thirard vear } \\ \text { Transition Paymment } \\ \text { Weight } \end{array} \end{aligned}\right.$ | $\begin{aligned} & \text { CY } 2010 \text { Third } \\ & \text { Year Transition } \\ & \text { Payment } \end{aligned}$ |
| 77332 | Radiaion treatment aid(s) |  | z3 |  | \$37.75 |
| 77333 | Radiaton treatment aid(s) |  | z3 |  | \$15.61 |
| 77334 | Radiation treamment ald (s) |  | z3 |  | \$69,26 |
| 77336 | Radialion physics consult |  | z3 |  | \$41.73 |
| 77338 | Design mic device for imft | Ni | 22 | 2.7055 | \$113.29 |
| 77370 | Radiation physics consult |  | 22 | 1.461 | \$61.18 |
| 77371 | Sis, multisurce |  | 22 | 104.238 | \$4,364,76 |
| 77399 | External raciation dosimetry |  | 22 | 1.461 | \$66.18 |
| 77401 | Radiation treatment deivery |  | 23 |  | \$20.15 |
| 77402 | Radiaion treatrientid doivery |  | 22 | 1.3668 | \$55.14 |
| 77403 | Radiation treament dolivery |  | 22 | 1.3168 | \$55.14 |
| 77404 | Radiaion lieatment deilivery |  | 22 | 1.3168 | \$55.14 |
| 77406 | Radiation treatment dolivery |  | 22 | 2.2033 | \$92.26 |
| 77407 | Radiation treatment dilivery |  | 22 | 1.3168 | \$55. 14 |
| 77408 | Radiation freatment dolivery |  | 22 | 1.3168 | \$55.14 |
| 77409 | Radiation treatment dolivery |  | 22 | 1.3168 | \$55.14 |
| 77411 | Radiation treatment deivivery |  | z2 | 2.2033 | \$92.26 |
| 77412 | Radiation treatment deivery |  | 22 | 2.2033 | \$92.26 |
| 77413 | Radiaton treatment delivery |  | 22 | 2.2033 | \$92.26 |
| 77414 | Radiaton treatment delivery |  | 22 | 2.2033 | \$92.26 |
| 77416 | Radialion fieatment dolivery |  | 22 | 2.2033 | \$92.26 |
| 77417 | Radiology port fimm |  | N1 |  |  |
| 77418 | Radiaion Ix deilivery, imit |  | z2 | 5.9784 | \$250.33 |
| 77421 | Stereoscopic x-ray guidance |  | ${ }^{\text {N }}$ |  |  |
| 77422 | Neutron beam t , simple |  | 22 | 2.2033 | \$92.26 |
| 77423 | Neutron beam ix. complex |  | Z2 | 2.2033 | \$92.26 |
| 77435 | Sbbr management |  | N |  |  |
| 77470 | Special radiatio treament |  | 23 |  | \$88.00 |
| 77520 | Proton trmt, simple wo comp |  | 22 | 13.3743 | \$560.02 |
| 77522 | Protont tmt, simple wicomp |  | 22 | 13.3743 | \$560.02 |
| 77523 | Proton trmt, intermediate |  | 22 | 17.4955 | ${ }^{\text {\$732.59 }}$ |
| 77525 | Proton tratment, complex |  | 22 | 17.4955 | \$732.59 |
| 77600 | Hyperthermia treatment |  | 22 | 5.4016 | \$226,18 |
| 77605 | Hyperthermia traatment |  | 22 | 5.4016 | \$226.18 |
| 77610 | Hyperthermia traament |  | 22 | 5.4016 | \$226.18 |
| 77615 | Hyperthermia treatment |  | 22 | 5.4016 | \$226.18 |
| 77620 | Hyperthermia traatment |  | 22 | 5.4016 | \$226.18 |
| 77750 | Intuse radioative materials |  | 23 |  | \$72.10 |

[^12]

[^13]| Addendum BB ... Final ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2010 (Including Ancillary Services for Which Payment is Packaged) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS Code | Short Descriptor | $\begin{aligned} & \text { CY } 2010 \\ & \text { Comment } \end{aligned}$ | $\begin{array}{\|l\|l\|} \hline \text { CY } 2010 \\ \text { Payment } \\ \text { Indicator } \end{array}$ | CY 2010 Third Year Transition Payment Weight | CY 2010 Third Year Transition payment |
| 78190 | Platelel survival, kneicics |  | z2 | 2.5656 | \$107.43 |
| 78191 | Platieie survival |  | 22 | 2.5656 | \$107.43 |
| 78195 | Lymph system imaging |  | z2 | 3.6682 | \$153.60 |
| 78199 | Blocdiymph nuclear exam |  | z2 | 3.6682 | \$153.60 |
| 78201 | LVer imaging |  | z3 |  | \$114.68 |
| 78202 | Liver imagng with flow | CH | z3 |  | \$128.59 |
| 78205 | Liver imaging (3D) | CH | 23 |  | \$14279 |
| 78206 | Liver image (30) with fow |  | z2 | 4.1271 | \$172.81 |
| 78215 | Liver and spleen imaging |  | 23 |  | \$118.94 |
| 78216 | Liverer spleen iniagefliow |  | $z 3$ |  | ${ }^{976.93}$ |
| 78220 | Liver funcion study |  | 23 |  | \$84.02 |
| 78223 | Hepalobiliary imaging |  | z2 | 4.1271 | \$172.81 |
| 78230 | Salivary gland imaging |  | 23 |  | \$100.77 |
| 78231 | Serial salvary imaging |  | 23 |  | \$75.79 |
| 78232 | Salivary gland function exam |  | 23 |  | ${ }^{574.94}$ |
| 78258 | Esoonhageel motilly study | $\mathrm{CH}^{\text {che }}$ | $z 3$ |  | \$137,39 |
| 78261 | Gastric mucosa Imaging |  | Z2 | 3.5113 | \$147.03 |
| 78262 | Gastroesophageal reflux exam |  | z2 | 3.5113 | \$147.03 |
| 78264 | Gastric emptying study |  | 22 | 3.5113 | \$147.03 |
| 78270 | Vit B-12 absorpition exam |  | 23 |  | \$50.53 |
| 78271 | Vitb-12 absplp exam, initlac |  | 23 |  | \$53.37 |
| 78272 | Vit B-12 absorp, combined |  | 23 |  | 355.92 |
| 78278 | Acute Giblood loss imaging |  | 22 | 3.5113 | \$147.03 |
| 78282 | GI proten lioss exam |  | z2 | 3.5113 | \$147.03 |
| 78290 | Meckels diveri exam |  | z2 | 3.5113 | \$147.03 |
| 78291 | Leveen/shunt patency exam |  | z2 | 3.5113 | \$147.03 |
| 78299 | GI Iuciear procediure |  | 22 | 3.5113 | \$147.03 |
| 78300 | Bone imaging, /limited area |  | 23 |  | \$102.48 |
| 78305 | Bone imaging, multiple areas | CH | 23 |  | \$135.41 |
| 78306 | Bone imaging, whole body |  | 22 | 3.5118 | \$147.05 |
| 78315 | Bone imaging, 3 phase |  | 22 | 3.5118 | \$147.05 |
| 78320 | Bone imaging (3D) | CH | 23 |  | \$142, 50 |
| 78399 | Musculoskelealal muctear exam |  | z2 | 3.5118 | \$147.05 |
| 78414 | Non-maging hearif furction |  | z2 | 4.3402 | \$181.74 |
| 78428 | Cardiac shunt Imaging |  | 23 |  | \$114.11 |
| 78445 | Vascular flow imaging | CH | 23 |  | \$104.75 |
| 78451 | Hit muscle image spect, sing | Ni | z3 |  | \$193.60 |
| 78452 | Ht muscle image spect, mult | N | 23 |  | \$283,30 |

[^14]

[^15]| HCPCS Code | Short Descriptor | $\begin{aligned} & \mathrm{CY} 2010 \\ & \text { Comment } \\ & \text { Indicator } \end{aligned}$ | $\begin{array}{\|l\|l\|} \hline \text { PYy } 2010 \\ \text { Payment } \\ \text { indicator } \end{array}$ | $\substack{\text { Cransion Third } \\ \text { Trear } \\ \text { Weight }}$ <br> Wayment | $\left\lvert\, \begin{gathered} \text { Cr } 0010 \text { Third } \\ \text { Year Tranastion } \\ \text { Payment } \end{gathered}\right.$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 78606 | Brain image wfow 4 + views |  | z3 |  | \$206.09 |
| 78607 | Brain imaging ( 30 ) |  | 23 |  | \$218.01 |
| 78608 | Brain imaging (PET) |  | 22 | 14.7231 | \$616.50 |
| 78610 | Brain fow imaging only | CH | z2 | 2.7917 | \$116.90 |
| 78630 | Cerebrosplina fluid scan |  | 23 |  | \$214.04 |
| 78635 | CSF ventriculcegraphy |  | $z^{2}$ |  | \$201.26 |
| 78645 | CSF shunt evaluation |  | 22 | 2.7917 | \$116.90 |
| 78647 | Cerebrospinal fluid scan |  | 23 |  | \$206.09 |
| 78650 | CSF leakage maging |  | 23 |  | ${ }^{\$ 210.63}$ |
| 78660 | Nuclear exam of tear flow | CH | 23 |  | \$102.76 |
| 78699 | Nerrous system nuclear exam |  | z2 | 2.7917 | $\$ 116.90$ |
| 78700 | Kidney i imaging, morphol |  | 23 |  | \$109.01 |
| 78701 | Kidney imaging with flow |  | 23 |  | \$134.27 |
| 78707 | K fowfunct Image wo drug |  | z3 |  | \$137.96 |
| 78708 | $K$ fowfunct image wdrug |  | z3 |  | 591.12 |
| 78709 | K fowfurut image, mutitipe |  | 22 | 4.6133 | \$193.17 |
| 78710 | Kidney imaging (3D) |  | z3 |  | \$141.37 |
| 78725 | Kidrey tunction study |  | z3 |  | \$59.61 |
| 78730 | Usinary bladder relention |  | 23 |  | \$48,54 |
| 78740 | Ureteral reflux study |  | z3 |  | \$133.70 |
| 78761 | Testicular imaging wiflow |  | $z 3$ |  | \$124.90 |
| 78799 | Genitourinary nuciear exam |  | 22 | 4.6133 | \$193.17 |
| 78800 | Tumor ir inaging, linited area |  | 23 |  | $\$ 110.71$ |
| 78801 | Tumor imaging, mult areas |  | 23 |  | \$151.02 |
| 78802 | Tumor i imaging, whole boay |  | 23 |  | \$203.82 |
| 78803 | Tumor imaging (3D) |  | z3 |  | \$216.59 |
| 78804 | Tumor imaging, whole body |  | ${ }^{23}$ |  | ${ }^{\text {S380.95 }}$ |
| 78805 | Abscess imaging, lid area |  | z3 |  | \$106.45 |
| 78806 | Abscess imaging, whole body |  | ${ }^{2} 3$ |  | \$213.47 |
| 78807 | Nuclear Iocalization/abscess | CH | 22 | 4.1771 | \$172.40 |
| 78808 | IVinij ra drug dx study |  | N1 |  |  |
| 78811 | Pet image, lda area |  | 22 | 14.7231 | \$616.50 |
| 78812 | Peli inage, skulithigh |  | 22 | 14.7231 | \$616.50 |
| 78813 | Peti image, fuil body |  | 22 | 14.7231 | 5616.50 |
| 78814 | Peti Image w/ct, imat |  | 22 | 14.7231 | \$616.50 |
| 78815 | Peti inage w/il, skulitiligh |  | 22 | 14.7231 | \$616.50 |
| 78816 | Peti image wctit tuil body |  | 22 | 14.7231 | \$516.50 |
| 78999 | Nuclear dilignosicic exam |  | 22 | 1.5972 | \$66.8 |

[^16]

NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
standard rate setting methoodology and the MPFS. Under carrent tav, the MPFS payment rates will have a negative update for CY
2010. For a discussion of those rates, we refer readers to tre CY 2010 MPFS final rule.


[^17]

[^18]

[^19]|  |  |  |  |  |  |  |  | 等 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $\begin{aligned} & 9 \\ & 80 \\ & 80 \\ & 0 \end{aligned}$ | $\begin{gathered} 1 \\ \\ \\ \hline \end{gathered}$ | $58$ | $\begin{array}{cc} 0 \\ 0 & 0 \\ y & 0 \\ 0 & 0 \\ 0 \end{array}$ |  |  |  |  |  | S |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $\stackrel{\rightharpoonup}{\circ}$ |  |  | $\left(\begin{array}{l} \mathrm{C} \\ \mathbf{o} \end{array}\right.$ | ¢ |  |
|  |  |  | $z \bar{z}$ | $\bar{z} \bar{z}$ | $\bar{z} \bar{z}$ | $\bar{z} \bar{z}$ | $\bar{z} \bar{z}$ | $2 \mid \sqrt{2}$ |  |  | z | $\bar{z} \mid z$ |  |  |  |  |  |  |  | － | ${ }_{5}$ |  |  |  | 12 | 지조 | N | NN |  |  |  | NT |
|  |  |  |  |  |  |  |  | ¢ |  |  |  |  |  |  |  |  |  |  | IT | $5$ | $1 \mathrm{I}$ |  |  | $\frac{\pi}{0} \mathrm{I}$ | $5$ | 퐁 | 동 |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 8 \\ & 0 \\ & 0 \\ & 0 \\ & 2 \end{aligned}$ |  |  |  | Blo | $\begin{gathered} 8 \\ \hline 6 \\ \hline \end{gathered}$ |  | $\begin{gathered} 9 \\ 5 \\ 5 \\ 0 \\ 0 \\ 0 \end{gathered}$ |  | 웅 |  |  |  |  |  | $\begin{gathered} 2 \\ 0 \\ 0 \\ 0 \\ 0 \\ \hline \end{gathered}$ | 8 | 鸸 |  |  | － | \％ | $\begin{aligned} & 9 \\ & 8 \\ & 8 \\ & 8 \end{aligned}$ | $\begin{aligned} F \\ \hline \end{aligned}$ |  | Bider |  | $\begin{aligned} & 8.5 \\ & \hline 8 \mathbf{8} \\ & \hline \mathbf{0} \\ & \hline 0 \\ & \hline \end{aligned}$ | 荡 | \％ | $\begin{gathered} 3 \\ 3 \\ 3 \\ 3 \\ \hline 0.0 \\ \hline 0 \end{gathered}$ |  |

[^20]

NOTE 1：The Medicare program payment is 80 percent of the total payment amount and beneticiary coinsurance is 20 percent of the total payment amount，except for screening flexible signt
75 percent and the beneficiary coinsurance is 25 percent．

NOTE 2：Payment indicators for radiotogy services（Z2，Z3）are based on a comparison of the tinnal rates according to the ASC
standard rate setting methodology and the MPFS．Under current aww the MPFS payment rates will have a negative update for CY
2010．For a discussion of those rates，we refer readers to the CY 2010 MPFS final rule．


NOTE 1：The Mcdicare program payment is 80 percent of the total payment amount and bencficiary coinsurance is 20 percent of the
total payment amount，except for screening fexible sigmoidoscopies and screening colonoscopies for which the programp payment is
75 percent and the bencficiary coinstrance is 25 percent．
NOTE 2：Payment indicators for radiology services（Z2，Z3）are based on a comparison of the final rates according to the ASC
standard rate setting methodology and the MPFS．Under current law，the MPFS payment rates will have a negative update for CY standard rate setting methodology and the MPFS．Under current taw，the MPFS payment
2010．For a discussion of those rates，we refer readers to the CY 2010 MPFS final rule．

Addendum BB－－Final ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2010 （Including
Ancillary Services for Which Payment is Packaged）

|  | $\frac{\infty}{5}$ |  |  |  |  |  |  |  | 2 8 8 8 | $\stackrel{\infty}{\infty}$ | $$ |  |  |  | $\stackrel{0}{\infty}$ |  |  |  |  | $\stackrel{\theta}{6}$ |  | $\begin{aligned} & \mathrm{a} \\ & \mathrm{~N} \\ & \mathrm{M} \\ & \mathrm{~B} \end{aligned}$ |  |  |  |  |  | $1^{6}$ |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\frac{5}{6}$ |  | $8$ | $8 \stackrel{8}{8}$ |  |  |  |  | $\begin{aligned} & -1 \\ & 8 \\ & 8 \\ & \hline \end{aligned}$ | $\stackrel{m}{8}$ | $\begin{aligned} & \stackrel{\rightharpoonup}{8} \\ & \stackrel{y}{6} \end{aligned}$ | $\begin{array}{\|c\|} \hline 8 \\ \hline 8 \\ \hline \end{array}$ | $\begin{aligned} & 8 \\ & \hline 8 \\ & \hline \end{aligned}$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | N | N | VIN | N | NN | NN | NN | N | NT | $N$ | $N$ | $N$ | N | Z | $\underline{Y}$ | 8 | \％ | 8 | 8 | － | 8 | $\triangle$ | 8 | － | 8 |  | ® | צ | צ | $\geq$ | 2 | 2 | z | \％ |  | $\checkmark$ |  |  | y |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | T |  | 5 |  | T |  | T | O | S |  |  | $z$ | $\bar{z}$ |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  | $\begin{gathered} \frac{n}{2} \\ \frac{2}{8} \\ \frac{3}{3} \\ \frac{3}{3} \\ \frac{3}{2} \\ \frac{0}{3} \\ \frac{2}{2} \end{gathered}$ |  |  |  |  |  |  |  |  |  |  |  |  |  | $\overline{0}$ |  |  |  |  | $5$ |  |  |  |  |  |  | $\frac{0}{2}$ |  |
| $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 1 \\ & 1 \end{aligned}$ |  | $3 .$ | 受逄 | $\begin{aligned} & 9 \\ & 58 \\ & 58 \\ & 8 \\ & 8 \end{aligned}$ |  | $8$ | $5$ | $\stackrel{9}{8}$ | $\frac{2}{8} / 8$ | $8$ | $\left\|\begin{array}{c} \infty \\ 0 \\ 0 \\ 0 \\ \hline \end{array}\right\|$ | $\begin{aligned} & 8 \\ & 8 \\ & 8 \\ & 8 \end{aligned}$ | $\begin{aligned} & 8 \\ & 88 \\ & 8 \\ & \hline \end{aligned}$ |  | $\overline{\mathrm{Y}}$ | 呂 |  |  |  |  | $\begin{aligned} & 7 \\ & \hline 8 \\ & 8 \\ & 8 \end{aligned}$ | $8$ | － | \％ | $\begin{aligned} & 8 \\ & 8 \\ & \hline 8 \end{aligned}$ |  |  | \％ | $\begin{aligned} & \text { n } \\ & 8 \\ & 8 \end{aligned}$ | $\stackrel{\%}{6}$ | $\begin{aligned} & 0_{0} \\ & 0 \\ & \hline \end{aligned}$ |  | 8 | $\left.\right\|_{0} ^{\infty}$ |  |  |  |  |  |  |

[^21]

[^22]| Addendum BB -- Final ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2010 (Including Ancillary Services for Which Payment is Packaged) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS Code | Short Descriptor | CY 2010 Comment Indicator | CY 2010 Payment indicator | $\begin{aligned} & \text { CY } 2010 \text { Third Year } \\ & \text { Transition Payment } \\ & \text { Weight } \end{aligned}$ | CY 2010 Third Year Transition Payment |
| J0289 | Amphotericin bliposome inj |  | K2 |  | \$14.96 |
| J0290 | Ampicillin 500 MG inj |  | Ni |  |  |
| J0295 | Ampiciilin sodium per 1.5 gm |  | N1 |  |  |
| J0300 | Amobarbital 125 MG inj |  | N1 |  |  |
| J0330 | Succinycholine chioride inj |  | N1 |  |  |
| J0348 | Anidulafungin injection |  | K2 |  | \$1.21 |
| J0360 | Hydralazine hel injection |  | N1 |  |  |
| J0364 | Apomorphine hydrochloride |  | N1 |  |  |
| J0365 | Aprotonin, $10,000 \mathrm{kiu}$ |  | K2 |  | \$2.60 |
| J0380 | Inj melaraminol bitartrate |  | N1 |  |  |
| J0390 | Chloraquine injection |  | N 1 |  |  |
| j0400 | Aripiprazole injection |  | N1 |  |  |
| J0456 | Azithromycin |  | N1 |  |  |
| J0460 | Atropine sulfate injection | CH | D5 |  |  |
| J0461 | Atropine sulfate injection | NI | N1 |  |  |
| J0470 | Dimecaprol injection |  | K2 |  | \$26.81 |
| J0475 | Bacioten 10 MG injection |  | K2 |  | \$195.31 |
| J0476 | Baciofen intrathecal trial |  | K2 |  | \$71.24 |
| J0480 | Basiliximab |  | K2 |  | \$1,624.44 |
| J0500 | Dicyclomine injection |  | N1 |  |  |
| j0515 | Inj beriztropine mesylate |  | N1 |  |  |
| J0520 | Bethanechol chloride inject |  | N1 |  |  |
| J0530 | Penicillin g benzathine inj | CH | D5 |  |  |
| J0540 | Penicililing benzathine inj | CH | D6 |  |  |
| J0550 | Penicililing benzathine inj | CH | D5 |  |  |
| J0559 | PenG benzathine/procaine inj | Ni | N1 |  |  |
| J0560 | Penicililin g benzathine inj |  | Ni |  |  |
| J0570 | Penicililing benzathine inj |  | N1 |  |  |
| J0580 | Penicililing benzathine inj |  | N1 |  |  |
| J0583 | Bivalirudin |  | K2 |  | \$2.40 |
| J0585 | Injection,onabotulinumtoxinA |  | K2 |  | \$5.40 |
| J0586 | Abobotulinumtoxitypea | N | K2 |  | \$8.23 |
| J0587 | Inj, rimabotulinumtoxinB |  | K2 |  | \$10.38 |
| J0592 | Buprenorphine hydrochlioride |  | N1 |  |  |
| J0594 | Busulfan injection |  | K2 |  | \$14.18 |
| J0595 | Butorphanol tatrate 1 mg |  | N1 |  |  |
| J0598 | C1 esterase inhibitior inj | N | K2 |  | \$41.34 |
| J0600 | Edetate calcium disodium inj |  | K2 |  | \$78.86 |

[^23]

[^24]| Addendum BB -- Final ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2010 (Including Ancillary Services for Which Payment is Packaged) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS Code | Short Descriptor | CY 2010 Indicator | $\begin{aligned} & \text { CY } 2010 \\ & \text { Payment } \\ & \text { Indicator } \end{aligned}$ | CY 2010 Third Year Transition Payment Weight | $\begin{aligned} & \text { CY } 2010 \text { Third } \\ & \text { Year Transition } \\ & \text { Payment } \end{aligned}$ |
| J0881 | Dabbepoetin alfa, non-esrd |  | K2 |  | \$2.76 |
| J0885 | Epoetin alfa, non-esrd |  | K2 |  | \$9.40 |
| J0894 | Decitabine injection |  | K2 |  | \$28.42 |
| J0895 | Deferoxamine mesylate inj |  | N1 |  |  |
| J0900 | Testosterone enanthate inj |  | N1 |  |  |
| J0945 | Brompheniramine maleate inj | CH | K2 |  | \$0.75 |
| J0970 | Estradiol valerate injection |  | N1 |  |  |
| 11000 | Depo-estradiol cypionate inj |  | N1 |  |  |
| J1020 | Methylprednisolone 20 MG inj |  | N1 |  |  |
| J1030 | Methylprednisolone 40 MG inj |  | N1 |  |  |
| J1040 | Melhylprednisolone 80 MG inj |  | Nt |  |  |
| J1051 | Medroxyprogesterone inf |  | N1 |  |  |
| J1060 | Testosterone cypionate 1 ML . |  | N1 |  |  |
| J1070 | Testosterone cypionat 100 MG |  | N1 |  |  |
| J1080 | Testosterone cypionat 200 MG |  | N1 |  |  |
| J1094 | Inj dexamethasone actate |  | N1 |  |  |
| J1100 | Dexamethasone sodium phos |  | N |  |  |
| J1110 | Inj dihydroergotamine mesyit |  | N1 |  |  |
| J1120 | Acetazolamic sodium injectio |  | N1 |  |  |
| J1160 | Digoxin injection |  | N1 |  |  |
| J1162 | Digoxin inmurie fab (ovine) |  | K2 |  | \$474.73 |
| J1165 | Phenytoin sodium injection |  | N1 |  |  |
| J1170 | Hydromorphone injection |  | N1 |  |  |
| J1180 | Dyphylline injection |  | N |  |  |
| J1190 | Dexrazoxane HCl injection |  | K2 |  | \$340.03 |
| ग1200 | Diphenhydramine hol injectio |  | N1 |  |  |
| J1205 | Chiorothiazide sodium inj |  | K2 |  | \$292.02 |
| 11212 | Dimethyl sulfoxide $50 \% 50 \mathrm{ML}$ |  | K2 |  | \$67.46 |
| J1230 | Methadone injection |  | Ni |  |  |
| J1240 | Dimenhydrinate injection |  | N1 |  |  |
| J1245 | Dipyridamole injection |  | N1 |  |  |
| J1250 | Inj dobutamine HCL/250 mg |  | N1 |  |  |
| J1260 | Dolasetron mesylate | CH | N1 |  |  |
| J1265 | Dopamine injection |  | N |  |  |
| J1267 | Doripenem injection |  | K2 |  | \$0.57 |
| J1270 | Injection, doxercalciferol |  | N1 |  |  |
| J1300 | Eculizumab injection |  | K2 |  | \$177.57 |
| J1320 | Amitriptyline injection |  | N1 |  |  |

[^25]

[^26]| Addendum BB - Final ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2010 (Including Ancillary Services for Which Payment is Packaged) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS Code | Short Descriptor | CY 2010 Comment Indicator | $\begin{aligned} & \text { CY } 2010 \\ & \text { Payment } \\ & \text { Indicator } \end{aligned}$ | CY 2010 Third Year Transition Payment Weight | CY 2010 Third Payment |
| J1569 | Gammagard liquid injection |  | K2 |  | \$37.85 |
| J1570 | Ganciciovir sodium injection |  | N1 |  |  |
| J1571 | Hepagam bimi ijection |  | K2 |  | \$50.04 |
| J1572 | Flebogamma injection |  | K2 |  | \$36.51 |
| 11573 | Hepagam b intravenous, inj |  | K2 |  | \$50.04 |
| J1580 | Garamycin gentamicin inj |  | N1 |  |  |
| J1590 | Gatifloxacin injection |  | N1 |  |  |
| J1595 | Injection glatiramer acetate |  | K2 |  | \$81.23 |
| J1600 | Gold sodium thiomaleate inj |  | N1 |  |  |
| J1610 | Glucagon hydrochioride/1 MG |  | K2 |  | \$79.20 |
| J1620 | Gonadorelin hydroch/ 100 mcg |  | K2 |  | \$176.89 |
| J1626 | Grarisetron hclinjection | CH | N1 |  |  |
| J1630 | Hatoperíiod injection |  | N1 |  |  |
| J1631 | Halopenidol decanoate inj |  | N1 |  |  |
| J1640 | Hemin, 1 mg |  | K2 |  | \$7.73 |
| J1642 | Inj heparin sodium per 10 u |  | N |  |  |
| J1644 | Inj heparin sodium per 10000 |  | N1 |  |  |
| J1645 | Dalteparin sodium |  | N1 |  |  |
| J1650 | Inj enoxaparin sodium |  | N1 |  |  |
| J1652 | Fondaparinux sodium |  | K2 |  | \$5.98 |
| J1655 | Tinzaparin sodium injection |  | N1 |  |  |
| J1670 | Tetanus immune globulin inj |  | K2 |  | \$199.91 |
| J1680 | Human fibrinogen conci ifj | Ni | K2 |  | \$96.46 |
| J1700 | Hydrocortisone acetate in] |  | N1 |  |  |
| J1710 | Hydrocortisone sodium ph inj |  | N1 |  |  |
| J1720 | Hydrocortisone sodium succi |  | N1 |  |  |
| J1730 | Diazoxide injection |  | K2 |  | \$112.16 |
| J1740 | Ibandronate sodium injection |  | K2 |  | \$139.22 |
| J1742 | Ibutilide fumarate injection |  | K2 |  | \$404.01 |
| J1743 | Idursulfase injection |  | K2 |  | \$446.44 |
| J1745 | Infliximab injection |  | K2 |  | \$57.60 |
| J1750 | Ind iron dextran |  | K2 |  | \$14.11 |
| ${ }^{17756}$ | Iron sucrose injection |  | K2 |  | \$0.37 |
| J1785 | Injection imiglucerase /unit |  | K2 |  | \$4.12 |
| J1790 | Droperidol injection |  | N1 |  |  |
| ग1800 | Propranolol injection |  | N 1 |  |  |
| J1815 | insulin injection |  | N1 |  |  |
| $J 1817$ | Insulin for insulin pump use | CH | K2 |  | \$3.34 |

[^27]

[^28]| Addendum BB -- Final ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2010 (Including Ancillary Services for Which Payment is Packaged) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS Code | Short Descriptor | CY 2010 Indicator | CY 2010 Payment indicator | CY 2010 Third Year Transition Payment Weight | CY 2010 Third Year Transition Payment |
| J2321 | Nandrotone decanoate 100 MG | CH | K2 |  | \$7.00 |
| J2322 | Nandrotone decanoate 200 MG | CH | K2 |  | \$14.74 |
| J2323 | Natalizumab injection |  | K2 |  | \$8.32 |
| J2325 | Nesiritide injection |  | K2 |  | \$36.07 |
| J2353 | Octreotide injection, depot |  | K2 |  | \$105.27 |
| J2354 | Octreotide inj, non-depot |  | N1 |  |  |
| J2355 | Opreverekin injection |  | K2 |  | \$242.16 |
| J2357 | Omalizumab injection |  | K2 |  | \$18.86 |
| J2360 | Orphenadrine injection |  | N |  |  |
| J2370 | Phenylephrine hicl injection |  | N1 |  |  |
| J2400 | Chloroprocaine hal injection |  | N1 |  |  |
| J2405 | Ondansetron hicl injection | CH | N1 |  |  |
| J2410 | Oxymorphone hal Iijection |  | N1 |  |  |
| J2425 | Palifermin injection |  | K2 |  | \$11.06 |
| J2430 | Pamidronate disodium $/ 30 \mathrm{MG}$ |  | K2 |  | \$18.42 |
| J2440 | Papaverin hel injection |  | N1 |  |  |
| J2469 | Palonosetron hal |  | K2 |  | \$17.19 |
| J2501 | Paricalcitol |  | N1 |  |  |
| J2503 | Pegaptanib sodium injection |  | K2 |  | \$1,014.11 |
| J2504 | Pegademase bovine, 25 iu |  | K2 |  | \$242,67 |
| J2505 | Injection, pegfiligrastim 6 mg |  | K2 |  | \$2,222.07 |
| J2510 | Penicililin g procaine ini |  | N1 |  |  |
| J2513 | Pentastarch 10\% solution |  | K2 |  | \$1,270.88 |
| J2515 | Pentobarbital socium in] | CH | N1 |  |  |
| J2540 | Penicililing potassium inj |  | N1 |  |  |
| J2543 | Piperacilinftazobactam |  | N1 |  |  |
| J2550 | Promethazine hol injection |  | N1 |  |  |
| J2560 | Phenobarbital sodium inj |  | N1 |  |  |
| J2562 | Plerixator injection | NI | K2 |  | \$268.51 |
| J2590 | Oxytocin injection |  | N1 |  |  |
| J2597 | Inj desmopressin acetate |  | N1 |  |  |
| J2650 | Prednisolone acelate inj |  | N1 |  |  |
| J2670 | Tofazoline hal injection |  | N1 |  |  |
| J2675 | Inj progesterone per 50 MG |  | N1 |  |  |
| J2680 | Fluphenazine decanoate 25 MG |  | N1 |  |  |
| J2690 | Procainamide hal injection |  | N1 |  |  |
| J2700 | Oxacillin sodium injeciton |  | N1 |  |  |
| J2710 | Neostigmine methylsifte inj |  | N1 |  |  |

[^29]

| Addendum BB -- Final ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2010 (Including Ancillary Services for Which Payment is Packaged) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS Code | Short Descriptor | CY 2010 Comment Indicator | CY 2010 Payment indicator | CY 2010 Third Year Transition Payment Weight | CY 2010 Third Year Transition Payment |
| J3101 | Tenecleplase injection |  | K2 |  | \$40.10 |
| J3105 | Terbutaline sulfate inj |  | N1 |  |  |
| J3120 | Testosterone enanthate inj |  | N1 |  |  |
| J3130 | Testosterone enanthate inj |  | N1 |  |  |
| J3140 | Testosterane suspension inj |  | N1 |  |  |
| J3150 | Testosteron propionate inj |  | N1 |  |  |
| J3230 | Chiorpromazine hal injection |  | N1 |  |  |
| J3240 | Thyrotropin injection |  | K2 |  | \$948,38 |
| J3243 | Tigecycline injection |  | K2 |  | \$1.15 |
| J3246 | Trofitian HCl |  | K2 |  | \$7.83 |
| J3250 | Trimethobenzamide hcl inj |  | N1 |  |  |
| J3260 | Tobramycin sulfate injection |  | N1 |  |  |
| J3265 | Injection torsemide $10 \mathrm{mg} / \mathrm{ml}$ |  | N1 |  |  |
| J3280 | Thiethylperazine maleate inj |  | N1 |  |  |
| J3285 | Treprostrinilinjection |  | K2 |  | \$54.83 |
| J3300 | Tramotinolone A inj PRS-free |  | K2 |  | \$3.20 |
| J3301 | Triamcinolone acet inj NOS |  | N1 |  |  |
| J3302 | Triamcinolone diacetate inj |  | N1 |  |  |
| J3303 | Triamcinolone hexacetonl inj |  | N1 |  |  |
| J3305 | Inif trimetrexate glucoronate |  | K2 |  | \$124.80 |
| J3310 | Perphenazine injeciton |  | N1 |  |  |
| J3315 | Triptorelin pamoate |  | K2 |  | \$160.83 |
| J3320 | Spectinomyen di-hcl inj |  | N1 |  |  |
| J3350 | Urea injection | CH | N1 |  |  |
| J3355 | Urofolititropin. 75 Iu |  | K2 |  | \$59.26 |
| J3360 | Diazepam injection |  | N1 |  |  |
| J3364 | Urokinase 5000 IU injection |  | N1 |  |  |
| J3365 | Urokinase 250,000 14 inj |  | k2 |  | \$449.09 |
| J3370 | Vancomycin hal injection |  | N1 |  |  |
| J3396 | Verteportin injection |  | K2 |  | \$9.31 |
| J3400 | Terflupromazine hcl inj | CH | N1 |  |  |
| J3410 | Hydroxyzine hot injection |  | N1 |  |  |
| J3411 | Thiamine hci 100 mg |  | N1 |  |  |
| J3415 | Pyidoxine hcl 100 mg |  | N1 |  |  |
| J3420 | Vitamin bi2 injection |  | N |  |  |
| J3430 | Vitarrin k phytonatione inj |  | N1 |  |  |
| J3465 | injection, voriconazole |  | K2 |  | \$5.26 |
| J3470 | Hyaluronidase injection |  | N1 |  |  |

NOTE 1: The Medicare program payment is 80 peccent of the total payment amount and bencficiary coinsurance is 20 percent of the
total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for $C X$
2010. For a discussion of those rates, we reter readers to the CY 2010 MPFS final rule. NOTE 1: The Medicare progrann payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the benefficiary coinsurance is 25 percent.

NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CY
2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.


[^30]| Addendum BB -- Final ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2010 (Including Ancillary Services for Which Payment is Packaged) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS Code | Short Descriptor | $\begin{array}{\|l\|} \hline \text { CY } 2010 \\ \text { Comment } \\ \text { Indicator } \end{array}$ | $\begin{aligned} & \text { CY } 2010 \\ & \text { Payment } \\ & \text { indicator } \end{aligned}$ | $\begin{aligned} & \text { CY } 2010 \text { Third Year } \\ & \text { Transition Payment } \\ & \text { Weight } \end{aligned}$ | $\begin{aligned} & \text { CY } 2010 \text { Third } \\ & \text { Year Transition } \\ & \text { Payment } \end{aligned}$ |
| J7322 | Syivisc inj per dose | CH | D5 |  |  |
| J7323 | Euflexxa inj per dose |  | K2 |  | \$113.96 |
| J7324 | Orthovisc inj per dose |  | K2 |  | \$177.68 |
| J7325 | Synvisc or Symvisc-One | N | K2 |  | \$11.47 |
| J7500 | Azathioprine oral 50 mg |  | N1 |  |  |
| J7501 | Azathioprine parenteral |  | K2 |  | \$90.64 |
| J7502 | Cyclosporine oral 100 mg |  | K2 |  | \$3.22 |
| J7504 | Lymphocyte immune glabulin |  | K2 |  | \$453.67 |
| J7505 | Monoclonal antibodies |  | K2 |  | \$1,109.45 |
| J7506 | Prednisone oral |  | N1 |  |  |
| J7507 | Tacrolimus oral per 1 MG |  | K2 |  | \$3.96 |
| J7509 | Meltyiprednisolone oral |  | N1 |  |  |
| J7510 | Prednisolone oral per 5 mg |  | N1 |  |  |
| J7511 | Anitthymocyte glabuin rabbit |  | K2 |  | \$414.44 |
| J7513 | Dacizumab, parenteral |  | K2 |  | \$378.20 |
| J7515 | Cyclosporine oral 25 mg | CH | K2 |  | 80.82 |
| J7516 | Cyclosporin parenteral 250 mg |  | K2 |  | \$21.24 |
| J7517 | Mycophenolate mofetil oral |  | K2 |  | \$2.45 |
| J7518 | Mycoohenolic acid | CH | N1 |  |  |
| J7520 | Sirolimus, oral |  | K2 |  | \$9.44 |
| J7525 | Tacrolimus injection |  | K2 |  | \$136.82 |
| J7599 | Immunosuppressive drug noc |  | N1 |  |  |
| J7674 | Methacholine chioride, neb |  | N1 |  |  |
| J7799 | Non-inhalation drug for DME |  | Ni |  |  |
| J8501 | Oral aprepitant |  | K2 |  | \$5.42 |
| J8510 | Oral busulian | CH | N1 |  |  |
| J8520 | Capecitabine, oral, 150 mg |  | K2 |  | $\$ 5.68$ |
| J8521 | Capecitabine, oral, 500 mg |  | K2 |  | \$18.73 |
| J8530 | Cyclophosphamide oral 25 MG |  | N1 |  |  |
| J8540 | Oral dexamethasone |  | N1 |  |  |
| J8560 | Etoposide oral 50 MG |  | K2 |  | \$0.45 |
| J8597 | Antiemetic drug oral NOS |  | N1 |  |  |
| J8600 | Meiliphalan oral 2 MG |  | N1 |  |  |
| J8610 | Methotrexate oral 2.5 MG |  | N1 |  |  |
| J8650 | Nabilone oral | CH | Ni |  |  |
| J8700 | Temozolomide |  | K2 |  | \$8.59 |
| J8705 | Topotecan oral |  | K2 |  | \$71.35 |
| J9000 | Doxorubicim hol iniection |  | N1 |  |  |

[^31]

[^32]| Addendum BB -- Final ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2010 (Including Ancillary Services for Which Payment is Packaged) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS Code | Short Descriptor | $\begin{array}{\|l\|} \hline \text { CY } 2010 \\ \text { Comment } \\ \text { Indicator } \end{array}$ | CY 2010 Payment indicator | CY 2010 Third Year Transition Payment Weerght | $\begin{aligned} & \text { CY } 2010 \text { Third } \\ & \text { Year Transition } \\ & \text { Payment } \end{aligned}$ |
| J9165 | Diethylstilibestrol injection |  | K2 |  | \$1.257.36 |
| 19170 | Docetaxel Injection | CH | D5 |  |  |
| J9171 | Docetaxel injection | N | K2 |  | \$16.95 |
| J9175 | Elicits b solution per mi |  | N1 |  |  |
| J9178 | [ [1], epirubicin hal, 2 mg |  | K2 |  | \$2.55 |
| J9181 | Etoposide injection |  | N1 |  |  |
| J9185 | Fludarabine phosphate inj |  | K2 |  | \$151.36 |
| J9190 | Fluorouracil injection |  | N1 |  |  |
| J9200 | Floxuridine : Injection |  | K2 |  | \$46.60 |
| J9201 | Gemcitabine hal iniection |  | K2 |  | \$139.10 |
| J9202 | Goserelin acetate implant |  | K2 |  | \$193.02 |
| J9206 | Ininotecan injection |  | K2 |  | \$13.18 |
| J9207 | Ixabepilone injection |  | K2 |  | \$63.74 |
| J9208 | Ifosfomide injection |  | K2 |  | $\$ 29.39$ |
| J9209 | Mesna injection |  | K2 |  | \$4.34 |
| J9211 | \|darubicin hil injection |  | K2 |  | \$96.70 |
| 19212 | Interferon alfacon-1 in] | CH | K2 |  | \$6.75 |
| 19213 | Interferon alfa-2ainj |  | K2 |  | \$10.60 |
| J9214 | Interferon alfa-2b inj |  | K2 |  | \$15.54 |
| J9215 | Interferon alfa-13 inj |  | K2 |  | \$17.89 |
| J9216 | Interferon gamma 1 -binif |  | K2 |  | \$294.03 |
| J9217 | Leuprolide acelate suspnsion |  | K2 |  | \$210.52 |
| J9218 | Levprolide acelate injeciton |  | K2 |  | \$5.29 |
| J9219 | Leuprolide acelate implant |  | K2 |  | \$4,728,88 |
| J9225 | Vantas implant |  | K2 |  | \$1.473.60 |
| J9226 | Suppreilin LA implant |  | K2 |  | \$14,875.43 |
| J9230 | Mechiorethamine hal inj |  | K2 |  | \$144.56 |
| J9245 | In] melphalan hydrochl 50 MG |  | K2 |  | \$1,622.81 |
| J9250 | Methotrexate sodium in] |  | N1 |  |  |
| J9260 | Methotrexate soclium inj |  | Ni |  |  |
| J9261 | Nelarabine injection |  | K2 |  | \$101.28 |
| J9263 | Oxaliplation |  | K2 |  | \$9.55 |
| J9264 | Paciltaxel protein bound |  | K2 |  | \$9.09 |
| J9265 | Paciliaxel injection | CH | N1 |  |  |
| J9266 | Pegaspargase injection |  | K2 |  | \$2,695.67 |
| J9268 | Pentostatin injection |  | K2 |  | \$1,399.56 |
| J9270 | Plicamycin (mithramycin) inj | CH | N1 |  |  |
| J9280 | Mitomycin 5 MG inj |  | K2 |  | \$17.74 |

[^33]

[^34]

[^35]| 은 |  |  |
| :---: | :---: | :---: |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  | $\begin{aligned} & 0 \\ & 8 \\ & 8 \\ & 0 \\ & 8 \\ & 0 \\ & 0 \\ & 2 \end{aligned}$ |  |

[^36]
[^0]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and bencficiary coinsurance is 20 percent of the
    otal payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is
    75 percent and the beneficiary coinsurance is 25 percent.
    NOTE 2. Payment indicators for radiology services (Z2, Z33) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CX standard rate setting methodology and the MPFS. Under current law, the MPFs payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^1]:    NOTE 1: The Medicare program payment is 80 percent of the total payrment amount and beneficiary coinsurance is 20 percent of the
    total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is
    75 percent and the beneficiary coinsurance is 25 percent.
    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^2]:    NOTE 1: The Mecticare programm payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is
    75 percent and the beneficiary coinsurance is 25 percent.

[^3]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is total payment amount, except for screening flexible sigmo
    75 percent and the bencficiary coinsurance is 25 percent.

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law , the MPS payment ratos will have a negative update for CY standard rate setting methodology and the MPFS. Under current taw, the MPFS payment
    2010. For a discussion of those rates, we refer ceaders to the CY 2010 MPFS final rule.

[^4]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and bencficiary coinsurance is 20 percent of the
    total payment amoount, except for screening flexibbes sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS paymen
    2010 . For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^5]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coiusurance is 20 percent of the
    total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is
    75 percent and the beneficiary coinsurance is 25 percent.
    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^6]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is
    75 percent and the bencficiary coinsurance is 25 percent.
    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010 . For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^7]:    NOTE 1: The Medicare programp payment is 80 percent of the total payment amount and beneficiary coinstrance is 20 percent of the
    (otal payment amount, except for screesing flexible sigmoidoscopies and screening colonoscopies for which the program payment is
    75 percent and the bencficiary coinsurance is 25 percent.

[^8]:     75 percent and the beneficiary coinsurance is 25 percent.

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a cormparison of the tinal rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPF payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^9]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and bencficiary coinsurance is 20 percent of the
    total payment amount, except for screening flexibes sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percen

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPF payme.
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^10]:    NOTE 1: The Mcdicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total payment amount, except for screening flexibies sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^11]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and bencficiary coinsurance is 20 percent of the
    1otal payment amount, except for screening fexible sigmoidoscopies and screening colonoscopies for which the progran payment is
    75 percent and the bencficiary coinsurance is 25 percent.
    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for $C X$ standard rate setting methodology and the MPFS. Under curtent law, the MPF payme.
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^12]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total paymentamount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is
    75 percent and the beneficiary coinsurance is 25 percent.
    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^13]:    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    tandard rate setting methoodology and the MPFS. Under curreant taw, the MPFS payment rates will have a negative update for CX standard rate setting methodology and the MPF.
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^14]:    NOTE 1: The Medicare program payment is 80 peccent of the fotal payment amount and beneficiary coinscrance is 20 percent of the
    total payment amount, except for screening fexible sigmoidoscopies and screening colonoscopies for which the program payment is total payment amount, except for screening flexibe sigmo
    75 percent and the beneficiary coinsurance is 25 percent.

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^15]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    iotal payment amount, except for screening fexible sigmoidoscopies and screening colonoscopies for which the program payment is
    75 percent and the beneficiary coinsurance is 25 percent.
    VOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS paymen
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^16]:    NOTE 1: The Medicare program payment is 80 percent of the total payment anount and beneficiary coinsurance is 20 percent of the
    total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the progran payment is 75 percent and the beneficiary coinsurance is 25 percent.

    NOTE 2: Payment indicators for tadiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPSS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^17]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total payment amount except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^18]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total payment anount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is
    75 percent and the beneficiary coinsurance is 25 percent.
     standard rate setting methodology and the MPFS. Under current Law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^19]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and benefficiary coinsurance is 20 percent of the
    total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is total payment amount, except for screening flexible sigm
    75 percent and the beneficiary coinsurance is 25 percent.

    NOTE 2: Payment indicators for radiology services $(Z 2, Z 3)$ are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment tates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^20]:    NOTE 1：The Medicare progrann payment is 80 peccent of the total payment amount and bencticiary coinsurrance is 20 percent of the
    total payment amount，except for screening flexible sigmoidoscopies and screening colonoscopies for which the program paymuent is
    75 percent and the beneficiary coinsurance is 25 percent．
    NOTE 2：Payment indicators for radiology services（Z2，Z3）are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS．Under current law，the MPFS payment rates will have a negative update for CY standard rate setting methodology and the MPFS．Under current law，the MPFS payment
    2010 ．For a discussion of those rates，we refer readers to the CY 2010 MPFS final rule．

[^21]:    NOTE 1：The Medicare program payment is 80 percent of the total payment amount and benefficiary coinsurarce is 20 percent of the
    total payment amount，except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is
    75 percent and the beneficiary coinsurance is 25 percent．
    NOTE 2：Payment indicators for radiology services（Z2，Z3）are based on a comparison of the tinal rates according to the ASC
    standard rate setting methodology and the MPFS．Under current law，the MPFS payment rates will have a negative update for CY standard rate setting methodology and the MPFS．Under curcent law，the MPFS payment
    20！0．For a discussion of those rates，we refer readers to the CY 2010 MPFS final rule．

[^22]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total payment amount, except for scyeening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the benefficiary coinsurance is 25 percen

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will lave a negative update for CX standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^23]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is total payment amount, except for screening hexibit sigm
    75 percent and the beneffiary coinsurance is 25 percent.

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^24]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is
    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPES payment rates will have a negative update for $C Y$ standard rate setting methodology and the MPFS. Under current law, the MPFS paymen
    2010. For a discussion of those rates, we reter readers to the CY 2010 MPFS final rule.

[^25]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coiusurance is 20 percent of the
    total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is
    75 percent and the bencficiary coinsurance is 25 percent.
    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the tinal rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law , the MPF payment rates will have a negative update for CY standard rate setting methodology and the MPES. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^26]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and bencficiary coinsurance is 20 percent of the
    total payment amount, except for screening flexibes sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current tav, the MPFS payment fates will have a negative update for CY
    20t0. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^27]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is total payment amount, except for screening hex ind
    75 percent and the beneficiary coinsurance is 25 pereent.

    NOTE 2: Payment indicators for tadiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS paymen
    2010. For a discussion of those rates, we reter readers to the CY 2010 MPFS final rule.

[^28]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    1otal payment amount, except for screening fexible sigmoidoscopies and screening colonoscopies for which the programp payment is
    75 percent and the beneficiary coinsurance is 25 percent.
    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methoodogegy and the MPFS. Under current taw, the MPFS payment rates will have a negative update for CY
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^29]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurarce is 20 percent of the
    total payment anount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is total payment amount, except for screening dexible
    75 percent and the beneficiary coinsurance is 25 percert.

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a cormparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^30]:    VOTE 1: The Mecticare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    otal payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the progran payment is
    75 percent and the bencficiary coinsurance is 25 percent.
    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CX standard rate setting methodology and the MPFS. Under current law, the MPFS paymee
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^31]:    NOTE 1: The Medicare program paryment is 80 percent of the total payment anount and beneticiary coinsurance is 20 percent of the
    total payment amount, except for screening flexibe sigmoidoscopies and screnning colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^32]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total payment ammount, except for screening flexibes sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CY standard rate setting methodology and the MPFF. Under current law, the MPFS paymen
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^33]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and bencficiary coinsurance is 20 percent of the
    total payment amount, except for ccreening flexibie sigooidoscopies and screening colonoscopies for which the program payment is total payment amount, except for screening flexible sigm
    75 percent and the beneficiary coinsurance is 25 percent.

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPS payment rates will thave a negative update for CY standard rate setting methodology and the MPFS. Under current law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^34]:    NOTE 1: The Medicare programm payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current taw, the MPFS payment rates will have a negative update for CX
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^35]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total payment amount except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

    NOTE 2: Payment indicators for radiology services (Z2, Z3) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current law, the MPFS payment rates will have a negative update for CY standard rate setting methodology and the MPFS. Under curcent law, the MPFS payment
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

[^36]:    NOTE 1: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the
    total payment amount, except for screening fiexibise sigmoidoscopies and screening colonoscopies for which the program payment is total payment amount, except for screening hex 25 percent and the bencficiary coiustrance is 25 percen.

    NOTE 2: Payment indicators for radiology services ( $Z 2, Z 3$ ) are based on a comparison of the final rates according to the ASC
    standard rate setting methodology and the MPFS. Under current taw, the MPFS payment rates will have a negative update for CY standard rate setting inethodology and the MPFS. Under current law, the MPFS payme,
    2010. For a discussion of those rates, we refer readers to the CY 2010 MPFS final rule.

